1. Introduction {#s0005}
===============

Carcinogens induce inflammation, an established hallmark of cancer ([@bb0890]; [@bb0960]; [@bb1655]). With potential exposure to greater than 15 million environmental chemicals worldwide, controlling inflammation and its resolution will be a critical component of the successful prevention and treatment of cancer ([@bb0850]; [@bb1930]; Sulciner, [@bb2245]). Uncontrolled local and systemic hyperinflammation is an underlying driving force of diseases including cardiovascular disease (e.g. atherosclerosis and myocardial infarction), abdominal aortic aneurysm, heart arrhythmias, arthritis, central nervous system disorders, periodontal disease, inflammatory bowel disease, gallstones, sepsis, infection, stroke/epilepsy, infection, acute respiratory distress syndrome (ARDS), fibrosis (e.g. liver, kidney and lung), portal hypertension, fatty liver, neurodegenerative diseases (e.g. Alzheimer\'s disease), traumatic brain injury, asthma, obesity, diabetes, pain, severe coronavirus disease (e.g. COVID-19), and autoimmune diseases ([@bb0385]; [@bb0445]; [@bb0705]; [@bb1160]; [@bb1510]; [@bb1710]; [@bb2230]; [@bb2385]). Over the past century, the study of anti-inflammatory mechanisms has focused on the suppression of pro-inflammatory mediators, such as cytokines, eicosanoids, and enzymes ([@bb2660]). In recent years, a new direction has emerged to "turn off" inflammation with the discovery of a new superfamily of endogenous specialized pro-resolving lipid-autacoid mediators (SPMs), such as resolvins, which have potent novel inflammation clearing ('pro-resolution') activity without being immunosuppressive ([@bb2230]; [@bb2255]; [@bb2265]). Unlike the majority of anti-inflammatory agents including the nonsteroidal anti-inflammatory drugs (NSAIDs) such as celecoxib and ibuprofen that work by directly suppressing cyclooxygenase (COX-2) enzyme activity, SPMs are endogenous inhibitors of inflammation, which function as "brake signals" to turn off inflammation ([@bb2230]). These pro-resolution lipid autacoids act through clearance of cellular debris by immune cells such as macrophage resulting in reduced localized pro-inflammatory cytokines in a process termed "resolution" ([@bb2230]). Failure of resolution via reduced SPMs (e.g. resolvins) is a key biological mechanism of pathogenesis and a unifying component of many underlying chronic inflammatory human diseases such as obesity, infection, asthma, wound healing, Alzheimer\'s Disease, Parkinson\'s disease, aging, sepsis, *Pseudomonas aeruginosa* infections, periodontitis, cardiovascular diseases, obesity, inflammatory bowel disease, neuroinflammation, respiratory diseases, multiple sclerosis, arthritis, cystic fibrosis, scleroderma, ocular disorders (e.g. age-related macular degeneration), atherosclerosis, rheumatic diseases, leukemia, sickle cell anemia, and chronic liver disease (e.g. cirrhosis) ([@bb0100]; [@bb0105]; [@bb0445]; [@bb0485]; [@bb0780]; [@bb0805]; [@bb1010]; [@bb1285]; [@bb1290]; [@bb1350]; [@bb1455]; [@bb1470]; [@bb1610]; [@bb1700]; [@bb1730]; [@bb1850]; [@bb1980]; [@bb2230]; [@bb2260]; [@bb2400]; [@bb2795]).

Inflammation was first described according to the four cardinal signs: calor (heat), pallor/dolor (pain), rubor (redness), and tumor (swelling), which reflect the pro-tumorigenic activity of cytokines, immune cells, and blood vessels (e.g. angiogenesis) in the tumor microenvironment ([@bb2235]; Sulciner, [@bb2245]). In healthy individuals, the acute inflammatory response(s) is self-limited and can be classically divided into initiation and resolution phases ([@bb2230]). Neutrophils (polymorphonuclear leukocytes) are one of the first immune cell types to enter the wounded area and remove microbes as well as cellular debris ([@bb2260]). Cancer is viewed as a wound that does not heal, thus attracting similar cell types and mechanisms as wound healing and tissue regeneration ([@bb0665]). A paradigm shift is emerging in our understanding of the pathogenesis of pathological inflammation which not only results from the persistent activation of inflammatory signals, but also the failure of engaging pro-resolving mechanisms including clearance of cell death "debris" and counter-regulation of pro-inflammatory cytokines ([@bb2230]; [@bb2260]). Experimental and human studies suggest that cancer progression results from the "failure to clear debris" after chemotherapy, radiation, or surgery ([@bb0375]; [@bb2330]; [@bb0795]; [@bb0825]; [@bb0850]; [@bb0910]; [@bb1125]; [@bb1930]; [@bb2085]; Sulciner, [@bb2245]; [@bb2875]). Thus, failure to engage resolution of inflammation mechanisms including clearance of debris may lead to carcinogenesis. Differentiating between suppression and resolution of inflammation is critical to mechanistic studies in inflammation-driven diseases including cancer ([@bb0760]; [@bb0850]; [@bb1390]; [@bb1930]; [@bb2230]; [@bb2280]; Sulciner, [@bb2245]; [@bb2875]).

A key concept in resolution of inflammation is that the immune system can be beneficial in fighting cancer, in accordance with the increasing interest in immune-mediated approaches in targeting cancer ([@bb2225]; [@bb2285]). In 1790 the Scottish surgeon John Hunter remarked "Inflammation in itself is not to be considered as a disease" ([@bb2565]). In 1893 William Coley successfully treated sarcomas with bacterial mixtures, leading to tumor regression ([@bb0500]). It has been known from the 11th Century "The Canon of Medicine," a historical encyclopedia of medical books, that inflammation is not entirely bad and can be good -- "pus bonum ert laudable" (good and laudable pus) ([@bb2225]). "Laudable pus" was believed to be a sign of a healthy, healing wound ([@bb0815]), and the Serhan laboratory discovered pro-resolution lipid mediators that are biosynthesized in the resolving inflammatory exudates to identify the "stop" signals which turn inflammation off ([@bb2230]; [@bb2255]; [@bb2265]; [@bb2250]). In Taber\'s Cyclopedic Medical Dictionary "resolution" is defined as "cessation of inflammation without suppuration; the return to normal" ([@bb2225]). Although it was previously believed that the resolution of inflammation was a passive process, it is now widely appreciated to be an active reprogramming of the immune environment regulated by pro-resolution lipid mediators ([@bb2230]; [@bb2255]; [@bb2265]; [@bb2260]). While blocking inflammation can be beneficial in cancer ([@bb0535]; [@bb0890]; [@bb1650]), stimulating the resolution of inflammation via pro-resolution mediators is an entirely distinct and unique approach from neutralizing pro-inflammatory factors via the clearance of pro-tumorigenic cellular debris ([@bb2230]; [@bb2260]). Pro-resolution mechanisms are multi-pronged including counter-regulating a series of pro-inflammatory mediators including cytokines, chemokines, and eicosanoids ("eicosanoid and cytokine storm") by stimulating the clearance of cellular debris (Sulciner, [@bb2245]).

2. Inflammation and Cancer {#s0010}
==========================

The relationship between inflammation and cancer harkens back over 150 years ago to 1863 when Rudolf Virchow suggested that chronic inflammation from tissue injury stimulates the proliferation of cells leading to cancer ([@bb0145]). Virchow\'s hypothesis that cancer is initiated at sites of "lymphoreticular infiltrate" is highly relevant to many cancer patients as pancreatitis, hepatitis, colitis, esophagitis, cholangitis, *Helicobacter pylori* and other chronic inflammatory diseases are established risk factors for cancer in these tissues ([@bb0200]; [@bb0885]; [@bb0905]; [@bb0900]; [@bb2135]). Virchow studied the four signs of inflammation (redness, swelling, heat and pain) and hypothesized a link between microinflammation and subsequent tumor progression ([@bb1045]). Experimental studies have indeed confirmed that inflammation can stimulate or induce tumor initiation, growth, and metastasis ([@bb0270]; [@bb0365]; [@bb0530]; [@bb0760]; [@bb0825]; [@bb0850]; [@bb0905]; [@bb1655]; [@bb1930]; Sulciner, [@bb2245]; [@bb2660]). Cancers arise frequently at sites of chronic inflammation and injury as the observation that secondary tumors occur at the points of injury (e.g. tumor growth next to surgical placement of glass rods) was noted in 1914 ([@bb1235]). The wound inflammatory response stimulates the growth of pre-neoplastic cells and cancer progression ([@bb0065]). Experimental evidence demonstrates that cancer therapies including chemotherapy, radiation, and surgery can stimulate tumor growth via a pro-tumorigenic host response including a eicosanoid/cytokine storm of pro-inflammatory and pro-angiogenic mediators ([@bb0325]; [@bb0365]; [@bb0740]; [@bb0760]; [@bb0825]; [@bb1270]; [@bb2270]; Sulciner, [@bb2245]; [@bb2620]). Wounding including surgery or biopsy can stimulate cancer growth via inflammation and angiogenesis ([@bb0040]; [@bb0800]; [@bb1065]; [@bb1360]; [@bb1425]; [@bb1930]).

Chronic inflammation and infection contributes to about 25% of all human cancers, including various tumor types such as hepatocellular, bladder and prostate cancer ([@bb0570]; [@bb0885]; [@bb2420]). For example, inflammation initiates cancer growth within 5 to 8 months in a genetically engineered model of pancreatic cancer ([@bb0905]). The importance of inflammation in cancer was further demonstrated in a randomized double-blind trial in patients with atherosclerosis. Patients who received canakinumab, an IL-1β inhibitor used to treat systemic inflammatory diseases, developed significantly reduced incidence of lung cancer and cancer-related mortality ([@bb2095]). Chronic inflammation also increases the risk of various malignancies such as those of the gastrointestinal tract including colorectal (CRC), gastric, gallbladder, and esophageal cancers ([@bb0010]; [@bb0705]; [@bb2660]). Increased infiltration of innate immune cells to the tumor, such as macrophages and neutrophils, correlates with increased angiogenesis and poor prognosis ([@bb2000]). In contrast, lymphocytic/monocytic inflammatory infiltrates can be associated with tumor inhibition and a beneficial prognosis ([@bb2955]). The inflammatory cells in the tumor may be genetically stable, and thus less susceptible to development of drug resistance making them an ideal target for new cancer therapies.

The traditional view that cancer is a cell-autonomous disease driven by genetic changes with selection for fast-growing and increasingly malignant cell clones has been supplanted with the understanding that cancer requires support from the host tissue microenvironment, including immune cells such monocytes/macrophages, neutrophils, and lymphocytes as well as endothelial cells, pericytes, fibroblasts and cancer stem cells ([@bb0790]; [@bb1245]). An early event in tumor progression is the recruitment of monocytes to the tumor site, where they differentiate into macrophages ([@bb0145]). Tumor infiltrating immune cells such as macrophages play a key role in tumor growth, angiogenesis, and inflammation ([@bb2000]) and exhibit critical crosstalk in tumor cell-stromal cell communication via pro-inflammatory and pro-resolution mediators ([@bb0850]; [@bb1930]; Sulciner, [@bb2245]).

Cancer therapies either directly (e.g. chemotherapy and radiation) or indirectly (targeted therapies such as immunotherapy and anti-angiogenic therapy) result in apoptotic tumor cell death ("tumor cell debris"). However, apoptotic cell death ("debris") is a double-edged sword and can paradoxically stimulate tumor growth and metastasis via pro-inflammatory mechanisms including a macrophage-secreted "cytokine and eicosanoid storm" of pro-angiogenic mediators ([@bb0365]; [@bb0760]; [@bb0825]; [@bb2085]; Sulciner, [@bb2245]). Therapy-induced inflammation and immune infiltration in cancer from chemotherapy, radiation, and immunotherapies can be beneficial by triggering anti-tumor immunity or stimulate tumor growth via immunosuppression ([@bb0890]). Over the past century anti-inflammatory therapies in cancer have focused on suppressing pro-inflammatory "go" signals such as cytokines, angiogenic factors and eicosanoids ([@bb0870]; [@bb2230]). Targeting inflammation and angiogenesis allows for the development of intervention strategies that can complement the traditional cell-autonomous cancer approaches which target the mutational capacity of tumors. Traditional anti-inflammatory agents such as steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), coxibs, and selective cytokine blockade exhibit potent anti-tumor activity in various pre-cancer models ([@bb2660]). Cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome (CYP) P450 enzymes and their inhibitors are widely used to treat inflammation and cancer. The prostaglandin receptors (e.g. EP1, EP2, EP3, and EP4) are overexpressed in cancers and are a target to treat various types of cancer, e.g. breast and colorectal cancer ([@bb1635]; [@bb2660]). Moreover, anti-inflammatories such as aspirin have exhibited potent chemopreventive activity in patients ([@bb0850]). However, in clinical trials anti-inflammatory agents have resulted only in transient anti-tumor activity, multiple toxicities, and immunosuppression severely limiting their use in cancer patients and healthy individuals with inflammatory disorders at risk for cancer (e.g. inflammatory bowel disease) ([@bb1745]; [@bb1930]; [@bb2160]; [@bb2230]). Side effects and toxicities from their immunosuppressive activity include impaired wound healing, fungal infections, osteoporosis, stomach bleeding, increased thrombosis, cardiovascular (e.g. heart attacks) and kidney toxicity ([@bb2230]; [@bb2660]). Moreover, anti-cytokine biologics designed to block pro-inflammatory factors may abrogate host defense against infections and increase risk of other cancers. In dramatic contrast, pro-resolution lipid mediators such as resolvins, lipoxins, protectins, and maresins are non-immunosuppressive, anti-thrombotic, anti-angiogenic, anti-fibrotic, stimulate the clearance of debris, stimulate tissue repair/regeneration, enhance postischemic revascularization, promote wound healing and exhibit potent biological activity at nanogram concentrations without overt toxicity reported to date ([@bb0430]; [@bb2120]; [@bb0850]; [@bb1050]; [@bb1210]; [@bb1870]; [@bb1930]; [@bb2050]; [@bb2260]; Sulciner, [@bb2245]; [@bb2965]).

3. Carcinogens and inflammation {#s0015}
===============================

A carcinogen is defined as a chemical substance, or a mixture of chemical substances, after inhalation, ingestion, dermal application or injection which induces cancer, increases its incidence, or shortens the time to tumor occurrence (i.e. latency) at any dosage level by any route in any species of animals as compared to controls ([@bb1600]). Examples include tobacco, natural and synthetic chemicals, and environmental toxins ([@bb1835]). Although it is challenging to estimate the number of cancer deaths caused by carcinogen exposure, an astonishing 70--95% of cancer cases can be traced to identified risk factors including diet (30--35%), tobacco (25--30%), infections (15--20%), obesity (10--20%), alcohol (4--6%), and others, including pollutants and radiation (10--15%) ([@bb0060]; [@bb1620]). Substances that induce tumors in animals are considered as presumed or suspected human carcinogens until convincing evidence to the contrary is presented ([@bb1695]). To establish a chemical as an human carcinogen requires experimental animal studies, human epidemiological cancer studies, clinical studies, and/or samples from human tissues exposed to the carcinogen to demonstrate a causal relationship ([@bb2410]). Many substances which have limited evidence from human studies but have sufficient evidence from animal carcinogenicity studies may also be carcinogens.

Since the 1970s the International Agency for Research for Cancer (IARC) has screened over 1000 agents which exhibited a cancer risk to humans ([@bb1370])**.** Over 100 carcinogenic agents can be divided into six general categories: (I) pharmaceuticals; (II) biological agents; (III) arsenic, metals, fibers and dusts; (IV) radiation; (V) personal habits and indoor combustions; and (VI) chemical agents and related occupations ([@bb1370])**.** Carcinogens including nitrosamines and aflatoxins can initiate or stimulate tumor growth and metastasis via multiple mechanisms including inflammation ([@bb2310]; [@bb2350]). Inflammation is a driving force for genotoxicity including impaired particle clearance leading to macrophage activation and persistent inflammation ([@bb0290]). Human carcinogens recently were categorized by 10 key characteristics of carcinogens including: (1) to be electrophilic or metabolically activated, (2) genotoxic, (3) alter DNA repair, (4) lead to epigenetic alterations or genomic instability, (5) generate oxidative stress, (6) chronic inflammation, (7) immunosuppression, (8) activate receptor mediated signaling, (9) cause cell immortalization and (10) alter cell proliferation, cell death, and angiogenesis ([Fig. 1](#f0005){ref-type="fig"} ) ([@bb2350]; [@bb2355]). These key characteristics of carcinogens provide a mechanistic basis to evaluate the activity of carcinogens (; [@bb0930]; [@bb2350]). Many carcinogens exhibit several of the 10 key characteristics, with an average of four characteristics per agent ([@bb1365]). These characteristics of carcinogens help to create the necessary tumor microenvironment for tumor initiation and progression via mechanisms distinct from the hallmarks of cancer ([@bb0925]; [@bb2350]; [@bb2355]). These key characteristics may also lead to the development of human-based assays and biomarkers for assessing cancer risk ([@bb0730]). At low concentrations, a chemical mixture has synergistic pro-tumorigenic activity on benign and malignant cells at a significantly lower concentration than as single chemicals ([@bb0560])**.** Carcinogens may not directly be genotoxic but cause DNA damage by stimulating inflammation. Chronic inflammation triggers oxidative stress via the release of pro-inflammatory cytokines and stimulation of cell proliferation, leading to DNA damage ([@bb1365]). Heavy metals such as arsenic, aluminum, nickel, cadmium, chromium, cobalt, palladium, and titanium induce severe damage triggering pro-inflammatory cytokines and oxidative stress ([@bb1230]; [@bb1630]). Carcinogens such as *per*- and polyfluoroalkyl substances (PFAS) cause cancer in animals and increase risk of cancer in humans via several key characteristics including oxidative stress, immunosuppression, and receptor-mediated activity ([@bb2475]). Primary genotoxicity can result from carcinogen-induced particles (e.g. from polycyclic aromatic hydrocarbons) while oxidative stress-induced DNA damage can induce secondary genotoxicity ([@bb2185]).Fig. 1Key characteristics of carcinogens.Represents the 10 key characteristics of carcinogens adapted from [Table 1](#t0005){ref-type="table"} in (M. T. [@bb2350]). Aflatoxin B~1~ as an example of a carcinogen which undergoes 1. Metabolic activation 2. Is genotoxic 3. Alters DNA repair 4. Leads to epigenetic alterations 5. Generates oxidative stress, 6. Chronic inflammation, and 7. Immunosuppression 8. Activates receptor mediated signaling 9. Causes cell immortalization and 10. Increases cell proliferation. Adapted from Smith et al. Environmental Health Perspectives 124:62016.Fig. 1Table 1SPM cancer-related mechanisms.Table 1Tumorigenic processSpecialized Pro-Resolving MediatorsMechanismsReferencesAnti-tumor\
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This important classification of key characteristics focused on the mechanisms of action of the cancer-causing activity of carcinogens provides a robust platform for novel chemopreventive treatment approaches to carcinogen-induced cancers. The carcinogenic potential of a compound is its ability to induce neoplasia via genotoxicity, cytotoxicity, proliferation, and inflammation depending on dose and duration of exposure ([@bb0635]). Importantly, inflammation can induces genetic changes which can cause cancer ([@bb1300]; [@bb1325])^,^. Cancer may be initiated with a mutation post-exposure to a DNA-damaging carcinogen, followed by pro-tumorigenic mechanisms such as inflammation which fuel the fire ([@bb0010]; [@bb0515]). Oxidative stress including reactive oxygen and nitrogen species (RONS) critically mediate cancer progression by carcinogens and pathogens ([@bb1300]; [@bb1715]). While oxidative stress can induce DNA damage and inflammation, repair of DNA lesions formed by RONS during chronic inflammation can protect from carcinogen-induced cancers ([@bb1715]). DNA damage also indirectly promotes inflammation through cytotoxicity ([@bb1300]). Excessive DNA damage during proliferation may not be cleared by DNA repair pathways, resulting in cell death including apoptosis, necroptosis, necrosis, or senescence. Thus, DNA damage is considered essential to carcinogenesis.

Initiators of carcinogenesis include radiation, certain chemotherapeutics and chemicals such as aflatoxin, urethane, tryptophan metabolites, and nitrosamines, can cause an irreversible genetic modification in a normal cell leading to cancer ([@bb0470]; [@bb1765]; [@bb2785]). Initiators can bind to and alter the DNA to generate adducts. The initiation stage is an event in which carcinogens usually induce mutations or other modifications in critical genes, which can produce cancer stem cells ([@bb1025]; [@bb2510]). A compound that acts as both an initiator and a promoter is referred to as a 'complete carcinogen' because tumor development can occur without the application of another compound ([@bb2070]). In studies of mouse skin carcinogenesis, a linear relationship has been observed between the dose of initiator and the quantity of tumors that can be produced ([@bb0855]). Thus, the more exposure to the carcinogen, the higher the risk of developing tumors ([@bb1255]). Cancer risk and slope factor are calculated in a linear dose-response ([@bb1255]). All known human carcinogens that have been studied for carcinogenesis in experimental animals have generated positive results in one or more animal species ([@bb2515]; [@bb2760]). For several carcinogens, such as aflatoxins and vinyl chloride, carcinogenesis in experimental models of cancer was established before epidemiological studies confirmed their carcinogenesis in humans ([@bb2580]).

The mechanism of action of carcinogens traditionally has been simplified as genotoxic and/or nongenotoxic. A genotoxic carcinogen is defined as a chemical that causes cancer by directly altering the genetic material of target cells, while non-genotoxic carcinogens are chemicals that can induce cancer by mechanisms not related to direct genetic damage. Many genotoxic carcinogens cause cancer in carcinogenic bioassays in animals ([@bb1445]). Concerning cancer risk assessment, genotoxic carcinogens exert carcinogenic potential regardless of the animal species. Thus, chemicals that are carcinogenic via genotoxicity to rodents are also presumed to be carcinogenic to humans unless proven otherwise. Because genotoxic carcinogens are mutagenic and may act through interaction with DNA to produce irreversible genetic changes in target organ cells, they may exhibit no dose threshold for their carcinogenic potential ([@bb2030]; [@bb2520]). A genotoxic chemical can induce mutations (e.g. induction of DNA modifications). Carcinogens may induce a specific gene mutation frequently observed in a particular cancer increasing the risk of cancer ([@bb1780]). While carcinogen-induced DNA damage can cause cancer, some studies suggest that DNA adducts alone or mutations alone may not be sufficient to cause cancer ([@bb0270]; [@bb1225]). Non cell-autonomous mechanisms such as inflammation and angiogenesis may also be critical to tumor initiation and progression ([@bb0790]). Importantly, proliferation of cells alone does not cause cancer as tumors can also develop in tissues subjected to infection, wounding, and inflammation ([@bb0530]; [@bb1360]; [@bb1930]).

Carcinogens (e.g. aflatoxins, nitrosamines, asbestos, dioxins, tobacco, and alcohol) can initiate and stimulate cancer progression through various mechanism including inflammation, oxidative stress, DNA damage*,* cytotoxicity, acute or chronic injury, and subsequent regenerative proliferation via cell death (e.g. apoptosis) ([@bb0270]; [@bb1335]; [@bb2865]). Environmental and occupational exposure to carcinogenic metals (e.g. arsenic, chromium, and vanadium) causes cancer via cell apoptosis, inflammation, DNA damage, and lipid peroxidation ([@bb0400]). There are over 8000 compounds identified as carcinogens to date. Carcinogens can stimulate cancer via the production of critical pro-inflammatory, pro-angiogenic and pro-tumorigenic cytokines/transcription factors, including TNF-α, IL-6, and NF-κB, as well as proto-oncogenes (e.g., c-Myc) ([@bb0395]; [@bb0830]). Moreover, carcinogens may impair the host protective immune response via immunotoxicity, including increased apoptosis of leukocytes and reactive oxygen species ([@bb1170]; [@bb1175]; [@bb1180]; [@bb1885]; [@bb2080]). Impaired resolution of inflammation can lead to many human diseases including cancer ([@bb0825]; [@bb1930]; [@bb2260]; Sulciner, [@bb2245]). Carcinogens can disrupt inflammation resolution by impairing host-protective immune cells (e.g. neutrophil and macrophage) phagocytosis of debris ([@bb0760]; [@bb1705]; [@bb1775]). Impaired clearance of debris fuels a pro-tumorigenic feedback loop between inflammation, DNA damage and carcinogenesis which can be aggravated by the tumor cell debris generated by cytotoxic cancer therapy including chemotherapy and radiation ([@bb0365]; [@bb0825]; [@bb1125]; Sulciner, [@bb2245]). Cross-talk between the cellular responses to DNA damage, RNA processing, and the extracellular vesicles mediate metastasis ([@bb1725]). Thus, differentiating between genotoxicity and non-genotoxicity mechanisms emphasizing the critical role of the tumor microenvironment including cancer stem cells (or tumor initiating cells), circulating tumor cells, inflammation and angiogenesis are critical for tumor initiation, tumor promotion, tumor dormancy escape and tumor progression ([@bb0045]; [@bb0140]; [@bb0820]; [@bb0945]; [@bb0950]; [@bb0955], [@bb0960]; [@bb2535]).

4. Human carcinogens {#s0020}
====================

More than 1400 chemicals and chemical groups are known or likely carcinogens. Human carcinogens include a wide range of substances from alcohol, nitrosamines, aflatoxins, physical stressors (e.g. UV and ionizing radiations), and infections include viruses-, bacteria- and parasites-induced infections (e.g. HIV, hepatitis, HPV and *H. pylori*). Infections, tobacco smoking, carcinogens (e.g. aflatoxins, nitrosamines, polycyclic aromatics), alcohol, obesity, inflammatory bowel disease and other diseases with a chronic inflammatory component have been associated with various cancers ([@bb1665]). Infectious agents including *Helicobacter pylori*, hepatitis B virus (HBV), hepatitis C virus (HCV), and human papillomavirus have been classified as carcinogenic agents in humans by International Agency for Research on Cancer (IARC). For example, almost half the world\'s population is infected by the pathogen *Helicobacter pylori*, categorized as a group I carcinogen, which is responsible for the highest rate of cancer deaths through the world ([@bb0460]). Carcinogens are grouped into aminoazo dyes, aromatic amines and amides, aromatic hydrocarbons, metals, natural compounds, olefins, and paraffines/ethers ([@bb1600]). Environmental exposures to soot, wood dust, vinyl chloride, sulfuric acid, coal emissions, nitrosamines, and other carcinogens may occur via occupations such as carpentry, plastic production, automobile manufacturing, mining and other industries ([@bb1060]; [@bb2115]; [@bb2370]). People can be exposed to chemical carcinogens such as trichloroeythylene in daily routines in house cleaning compounds, benzidine which used to be used often for color dyes, or asbestos found in housing insulation ([@bb1395]).

While exposure to certain carcinogens has declined with preventative education, other carcinogens cannot be completely avoided as they occur naturally or in the diet. Aflatoxins are mycotoxins produced by fungi which may contaminate a large portion of the world\'s food supply leading to cancer progression including hepatocellular carcinoma (HCC) ([@bb1670]; [@bb2790]; [@bb2940]). Other natural carcinogens include minerals like cadmium, nickel or erionite, thorium, crystalline silica, ultraviolet light, or radon gases. Arsenic can be found in contaminated ground water. Polycyclic aromatic hydrocarbons (PAH), such as benzo\[*a*\]pyrene (BaP) or dibenz\[*a*,*h*\]anthracene (DBA), can also be ingested in the diet or result in exposure in work environments ([@bb1600]; [@bb1990]).

Two of the most common human carcinogens are alcohol and tobacco, which is the leading risk factor for lung cancer with up to 80% of lung cancer deaths resulting from smoking inducing inflammation mechanisms such as increased macrophage recruitment, delayed clearance of neutrophils, and stimulation of reactive oxygen species ([@bb2650]). While ethanol is not genotoxic nor mutagenic, its metabolite acetaldehyde is a potent local carcinogen ([@bb2155])**.** Tobacco smoke is also associated with many other carcinogens such as benzene, naphthalene, cadmium, and nickel compounds. Environmental risk factors for bladder cancer, for example, include tobacco smoking, occupational exposure to aromatic amines, exposure to arsenic, chronic infection with *Schistosoma* species, radiation therapy to nearby organs, and the use of alkylating agents ([@bb0810]; [@bb0895]; [@bb1220]), and smokers are more than twice as likely to get bladder cancer than non-smokers. Moreover, the increased risk from smoking, although progressively decreasing after cessation, remains elevated by 62% and 50% even after 25 and 32 years, respectively ([@bb0305]). The carcinogen alcohol can lead to 4--6% of cancers ([@bb1620]). Chronic consumption of alcohol stimulates inflammation due to leakage of bacteria and bacterial products, predominantly lipopolysaccharide (LPS), from the gut into the bloodstream and the liver.

Aflatoxins are a group of mycotoxins produced by *Aspergillus* fungi which are natural carcinogens and contaminate a large portion of the world\'s food supply including grains and other food sources in tropical and subtropical climates, wetlands, and high temperatures. Up to 5 billion people exposed to aflatoxins are at increased risk for developing hepatocellular carcinoma (HCC) as the carcinogen causes up to 28% of HCC cases globally ([@bb1565]; [@bb2405]; [@bb2825]). Although aflatoxins have been primarily characterized as hepatocarcinogens, they are also carcinogenic in other tissues including mammary and lung ([@bb0685]; [@bb2850]; [@bb2880]). Aflatoxins have been linked to high levels of gallbladder cancers in Bolivia and Peru, as well as esophageal squamous cell carcinomas in China ([@bb0110]; [@bb2790]). Aflatoxins require bioactivation to reactive epoxides for genotoxic activity. The carcinogenicity of aflatoxins can result from metabolic activation of AFB~1~ to a genotoxic epoxide, with a high prevalence of point mutations in the p53 gene ([@bb0370]; [@bb2470]). AFB~1~ exposure can induce genotoxicity as reflected by sister chromatid exchange, micronuclei, chromosomal alterations, and DNA and protein adducts ([@bb1135]). Aflatoxin precursors and metabolites can generate cytotoxic and immunosuppressive nongenotoxic activity ([@bb0240]). AFB~1~ exhibits the highest hepatotoxic potential and has synergistic carcinogenic effects with fumonisin B~1,~ another hepatocarcinogen, as well as with lipopolysaccharide (LPS), hepatitis C, and alcohol ([@bb0005]; [@bb0185]; [@bb0465]). Aflatoxins have demonstrated genotoxic as well as nongenotoxic mechanisms of carcinogenesis including significant numbers of DNA-adducts from AFB~1~ from HCC analysis ([@bb0390]; [@bb2710]).

Triclosan (TCS) is a chemical that is commonly used in toothpaste, cosmetics, cooking materials, and other products as an antimicrobial but has recently been identified as a possible carcinogen. Up to 75% of people in the United States have likely been exposed to the chemical ([@bb2725]). Importantly, this carcinogen exposure induces an inflammatory response even at very low doses by activating TLR4 signaling and altering gut microbiota predisposing to colon carcinogenesis ([@bb2820]). TCS has been found in fluids and tissues of people of all ages and has demonstrated a wide range of effects including endocrine disruption, induction of inflammation and oxidative stress, epigenetic alterations, and carcinogenicity ([@bb2900]).

The perfluorinated carboxylic acids (PFCAs) are a family of synthetic perfluorinated compounds that include perfluorooctanoic acid (PFOA, also known as C8), perfluorooctane sulfonate (PFOS), and perfluorononanoic acid (PFNA). PFOA has been used in the manufacture of items such as Teflon non-stick coating, Gore-Tex water-repellent gear, microwave popcorn bags, carpet, and fire-fighting foam ([@bb1855]). Most carcinogens such as PFOA frequently exhibit several modes of action in causing cancer in animals. For example, PFOA can initiate and cause cancer through promoting oxidative stress and DNA damage ([@bb1335]; [@bb2865]). PFOA can also stimulate breast and colon cancer cell invasion via matrix metalloproteinases (MMPs) ([@bb1735]; [@bb2930]).

Nitrosamines including *N*-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) play a critical role in the initiation stage of carcinogenesis ([@bb1085]; [@bb2075]). IARC has classified NDMA and NDEA as probable carcinogens to humans (Group 2A) ([@bb2705]). NDMA induces cancer via a dose-response ([@bb1970]). NDMA has demonstrated highly carcinogenic, mutagenic, and teratogenic activity ([@bb0590]; [@bb0765]; [@bb2970]). Nitrosamines have been associated with an increased risk of many cancers including gastric, esophageal, nasopharyngeal, and bladder cancers ([@bb0190]; [@bb1750]). N-nitroso compounds are used as a prototype carcinogens to induce various types of cancer in animal models, including liver, lung, bile duct and pancreatic ([@bb2290]). In a large matched case--control study of pancreatic cancer, a significant positive association was found for NDEA, NDMA and pancreatic cancer ([@bb3020]). Moreover, extensive studies have demonstrated the cytotoxicity, genotoxicity, carcinogenicity, mutagenicity, as well as reproductive and developmental toxicity of nitrosamines ([@bb0410]; [@bb2885]; [@bb3005]; [@bb3030]). Tumors in multiple organs have been induced by nitrosamine compounds in 39 species including higher primates ([@bb0275]). NDMA causes cancer both as a single dose and with long-term exposure to lower quantities ([@bb2015]). Other carcinogens such as dibenzo\[*a*,*l*\]pyrene (DBP) can potently transform cells, even in the absence of detected DNA adducts ([@bb1845]).

5. Carcinogenesis is a multi-stage, multi-mechanism process {#s0025}
===========================================================

Although epidemiology and studies with human tissues or cells are relevant to carcinogen exposure in humans, the mechanistic of action studies underlying carcinogenesis are focused in animal models for obvious ethical considerations. Laboratory animals are routinely utilized to mimic cancer in humans because there are more genetic, physiologic, biochemical, and metabolic similarities than differences to humans, large sample size, reproducibility, and feasibility to generate various cancers as well as study the mechanism of action of carcinogens ([@bb1695]). For example, NDMA is a powerful carcinogen which induces 100% incidence of transitional cell carcinoma of the urinary bladder in the rat and the Syrian golden hamster ([@bb1520]; [@bb2090]). An example of an initiation-promotion model is a DMBA-induced, phorbol 12-myrisate 13-acetate (PMA) promoted or 12-*O*-tetradecanoylphorbol-13-acetate (TPA)-promoted squamous cell carcinoma ([@bb1770]; [@bb1805]). A frequent model of colon carcinogenesis is induced by azoxymethane (AOM) and promoted with dextran sodium sulfate (DSS) ([@bb1000]; [@bb2800]; [@bb2820]). *N*-nitrosomethylbenzylamine (NMBA)-induced tumorigenesis in esophagus is a model of human esophageal squamous cell carcinoma used for investigations of chemical carcinogenesis ([@bb0340]; [@bb2805]). Nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung cancer is commonly used to study mechanisms of lung and smoking-induced carcinogenesis ([@bb2100]; [@bb3010]). 4-nitroquinaline 1-oxide (4-NQO) is utilized to induce tongue and oral cancers ([@bb2810]). N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) is used to create a mouse model of human muscle invasive bladder cancer to study histological, physiological, molecular, and mutational mechanisms of carcinogenesis ([@bb0715]). Various chemically induced cancer models reflect various routes of exposure as tools to study mechanisms of carcinogens ([Fig. 2](#f0010){ref-type="fig"} ).Fig. 2Experimental models of carcinogen-induced cancers.A) Intraperitoneal injection of male Sprague-Dawley rats with 30 mg/kg Diethylnitrosamine (DEN) twice a week for 11 weeks led to hepatocellular carcinoma B) Male C57BL/6 J mice or BALB/c mice injected intraperitoneally week one with 10 mg/kg azoxymethane (AOM) and one week later given 1.5% or 2% dextran sodium sulfate (DSS) in the drinking water for one week leading to colon carcinomas. C) Male F344 rats given 20 p.p.m. 4-nitroquinoline 1-oxide (4-NQO) in drinking water for 10 weeks led to tongue squamous cell carcinoma or papilloma. D) NMRI mice exposed to single epicutaneous application of 0.1 μmol 7,12-dimethylbenz\[*a*\]anthracene (DMBA) in acetone and two weeks later exposed twice a week to 5 nmol phorbol 12-myrisate 13-acetate (PMA) for 28 weeks leading to skin papilloma and carcinoma. E) Male A/J mice were injected intraperitoneally with 50 mg/kg 4-(methylnitrosamino)-1 (3-pyridyl)-1-butanone (nicotine-derived nitrosamine ketone (NNK)) for 4 weeks led to lung adenocarcinoma. F) Male F344 rats injected subcutaneously with 1 mg/kg *N*-nitrosomethylbenzylamine (NMBA) 5 times a week for 5 weeks and then once a week for 5 more weeks led to esophageal papilloma and carcinomas.Fig. 2

Carcinogenesis, the process of initiating and stimulating cancer, is viewed as a multi-hit/multi-step process from the transition of normal cells into cancer cells via multiple mechanisms of action. In experimental cancer models, carcinogenesis is a multi-stage, multi-mechanism process, consisting of the "initiation," "promotion," and "progression" ([@bb2730]). The well-established mouse skin model is an important tool to study the mechanisms of multistage carcinogenesis ([@bb1685]; [@bb1955]; [@bb2345]; [@bb3055]). Initiation can be induced by the topical application of the carcinogen 7,12-dimethylbenz\[*a*\]anthracene (DMBA), which is potently immunosuppressive. Here, mutations are not sufficient to induce malignant transformation. In the mouse skin model the first stage involves a tumor initiator with the genetic material of stem cells leading to changes in growth control and/or differentiation. The major activity of tumor promoters is the specific expansion of the initiated stem cells in the skin ([@bb1955]; [@bb2345]). This can occur by both direct and indirect mechanisms that involve the direct growth stimulation of the initiated cells or cytotoxicity ([@bb1955]). Promotion of tumorigenesis is generated by the topical application of phorbol esters such as TPA to the skin, leading to epithelial cell proliferation with increased expression of the ligand EGF as well as cyclin D1, c-Jun, c-Fos, and c-Myc ([@bb0615]). TPA-treated mice form multiple benign papillomas and conversion to malignant squamous carcinomas within 10--20 weeks. An initiated cell can be amplified to a premalignant lesion, such as a papilloma in the skin, a nodule in the breast, or a polyp in the colon eventually invading and metastasizing to distal sites (the "progression" phase) (Trosko & [@bb2540]).

Notably, bacterial and viral infections can also be carcinogenic. *Helicobacter pylori*, hepatitis B or C, Epstein-Barr virus, and other infections are associated with increased cancer risk and carcinogenesis ([@bb1790]). In a mouse model benzo(*a*)pyrene (BaP) and lipopolysaccharide (LPS) promote lung tumorigenesis ([@bb1115]). Multiple liver infections including liver fluke and *Clonorchis sinensis* administered with NDMA cause experimental cholangiocarcinoma ([@bb1315]; [@bb1410]). Hepatitis C virus is synergistic with AFB~1~ in hepatocarcinogenesis including an enhanced inflammatory response and lipid peroxidation ([@bb1190]; [@bb1580]). While viral or bacterial infections can induce DNA methylation indirectly via chronic inflammation, certain viruses have direct activity on the epigenetics of host cells ([@bb1005]).

Anti-bacterial agents can improve outcome by reducing associated inflammation and manipulating the microbiome in colon carcinogenicity models ([@bb1000]). Parasite infection results in immune responses to generate nitrosamines (NDMA) in humans ([@bb2170]). Additionally, carcinogens such as aflatoxin B~1~ may promote influenza viral replication demonstrating synergy between environmental toxins and infections in causing cancer ([@bb2440]). The immune response to bacterial infection including stimulated eicosanoid production (e.g. prostaglandin E~2~ (PGE~2~) and cytokines (e.g. IL-8) shows the tight association between carcinogenesis and the immune response, particularly an inflammatory response ([@bb0245]).

6. Detection of carcinogens {#s0030}
===========================

An important strategy to prevent carcinogen-induced cancers is the detection of environmental carcinogens. Biomonitoring is critical to evaluating exposure to chemical carcinogens and involves the measurement of chemicals or their metabolites in various human samples including blood, urine, breast milk, and hair. Carcinogens can originate from various sources such as heavy metals, pesticides, industrial chemicals, commercial products and solvents. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis is a powerful analytical technique utilized to detect genotoxic and non-genotoxic chemicals (e.g. in the environment and food) at very low concentrations ([@bb0700]). One-step competitive enzyme immunoassays have been developed for monitoring carcinogen (e.g. fumonisin B1 and ochratoxin A) contamination in food such as cereals ([@bb1560]; [@bb2320]). Many genotoxic carcinogens may also be detected via DNA binding assays with a new biosensor assay detecting carcinogens in contaminated food samples with a 24-base guanine rich DNA segment at ranges as low as 0.0001 ppm ([@bb2165]). DNA adducts formed from genotoxic carcinogens can be identified in exposed people. Environmental carcinogens can be detected in serum, blood, and urine samples allowing for the measurement of chemicals such as tobacco and lead ([@bb1975]). Detection methods including electrochemical detection, mass spectrometry, fluorescence, and immunohistochemistry, have advanced to accelerator mass spectrometry, which can detect about 1 in 10^12^ nucleotides if labeled with a heavy isotope. Importantly, this mass spectrometry technique can be used to identify DNA as well as protein adduct formation to more accurately determine chemical carcinogen exposure in human populations ([@bb1995]). A metabolomics approach can predict the activity of non-genotoxic carcinogens via alterations in the levels of eicosanoids and reactive oxygen species ([@bb0050]).

7. Mechanisms of pro-tumorigenic activity by carcinogens {#s0035}
========================================================

7.1. Genotoxicity and mutations {#s0040}
-------------------------------

Genotoxicity is measured via a series of in vitro and in vivo assays such as gene mutations in bacteria and mammalian cells; chromosomal aberrations, micronuclei formation, unscheduled DNA synthesis or DNA damage in mammalian cells and in rodents. Environmental mutagens such as ultraviolet light or cigarette smoke can lead to a high mutation rate in certain cancer types (e.g., skin and lung) ([@bb2390]). Carcinogens can act as environmental stress factors and induce cancer-promoting genotoxicity by binding and mutating DNA via adduct formation. Carcinogens are metabolized by the human body to generate DNA-reactive species. Further, carcinogens can induce epigenetic changes which can lead to cellular transformation. DNA repair is critical for cancer prevention as DNA repair prevents the genetic mutations in normal cells ([@bb1300]). Examples of genotoxic carcinogens include NDMA or 4,4′-methylenedianiline (MDA) which bind directly to DNA generating adducts, DNA damage, and mutations ([@bb1345]). Cancer risk is determined beyond only DNA mutations. Aflatoxin B~1~ (AFB~1~) exposure generates genetic mutations via DNA adducts and is associated with a specific mutational pattern, including a mutational signature of *TP53,* in humans with aflatoxin-induced HCC ([@bb0225]; [@bb0380]). Nitrosamines, including NDMA, are mutagenic, genotoxic, and carcinogenic, even at low doses ([@bb2630]; [@bb2680]). Genotoxic carcinogens, such as NDMA, can induce DNA double-strand breaks in the comet assay and induce transformation of non-tumorigenic cells, such as NIH3T3 fibroblasts, to cancer causing cells ([@bb1415]; [@bb1575]11; [@bb2710]; [@bb2765]). Genotoxicity induced by NDMA is further demonstrated in extrahepatic tissues of rats by the persistence of DNA damage in the lung, liver, kidney and nasal cavity ([@bb0300]; [@bb2005]; [@bb2010]). Also, N-nitroso compounds such as NDMA activate *ras* oncogenes, which play a pro-tumorigenic role in the development of various cancers (e.g., colon) ([@bb2530]). DNA damage induced by NDEA increases micronuclei due to DNA breakage that could not be repaired, leading to an increase in chromosomal aberrations, and apoptotic cell death which can lead to cancer ([@bb0020]; [@bb0760]). Thus, carcinogens can initiate tumor growth via genotoxic mechanisms in synergy with nongenotoxic processes including cell death, inflammation, oxidative stress, angiogenesis and tissue injury.

7.2. Nongenotoxic mechanisms {#s0045}
----------------------------

Non-cell-autonomous contribution to tumorigenesis from the non-transformed "host-tissue", epitomized by tumor vasculature and inflammation, are crucial for tumor expansion and progression ([@bb0235]; [@bb0790]; [@bb0890]). The tumor stroma is comprised of a variety of cells essential for tumor growth, including "tumor associated" fibroblasts, inflammatory cells (e.g. macrophages), and the pericytes surrounding the tumor endothelium ([@bb0945]). Nongenotoxic carcinogens such as 1,4-dichloribenzene (DCB), phenobarbital sodium (PB), benzene, asbestos, arsenic or piperonyl butoxide (PBO) do not interact directly with DNA but promote carcinogenesis via other key characteristics of carcinogens ([@bb2350]; [@bb2355]). Many carcinogens can exhibit both genotoxic and nongenotoxic activities. In a study of mRNA biomarkers following carcinogen exposure signatures of nongenotoxic carcinogens involved cell injury and necrosis leading to regenerative proliferation, as well as immunosuppression ([@bb1345]). However, many chemicals considered to be nongenotoxic carcinogens actually possess certain genotoxic activities ([@bb1720]6). Importantly, chronic inflammation can lead to genetic instability and DNA damage without direct DNA adduct mechanisms of genotoxic carcinogens, which along with the ability to dysregulate DNA repair pathways potently promotes carcinogenesis ([@bb1650]). Interestingly, both genotoxic, and non-genotoxic carcinogens generate oxidative stress as an underlying cause for carcinogenesis ([@bb0585]). A new highly innovative model of carcinogenesis has been proposed as the Inflammation Somatic Model (ISM) based off the 2-stage somatic mutation model suggesting genotoxic effects are not sufficient to promote carcinogenesis and that inflammation as well as oxidative stress can prime tissues for cancer growth ([@bb0270]). Importantly, AFB~1~-induced hepatocarcinogenesis was prevented in rats with systemic administration of an anti-inflammatory and antioxidant CDDO-Im despite significant DNA adduct burden suggesting a protective effect and a DNA damage threshold ([@bb0670]; [@bb1225]). Thus, carcinogens can generate a feedforward cycle of tissue damage, inflammation, oxidative stress, mutagenesis, cell death, and subsequent regeneration and carcinogenesis ([Fig. 3](#f0015){ref-type="fig"} ).Fig. 3Nongenotoxic mechanisms of carcinogenesis.Following carcinogen exposure inflammation is induced leading to inflammatory infiltrates at the location of exposure. With the upregulation of NF-κB, COX-2, and 5-LOX inflammatory cells are triggered to release a storm of pro-inflammatory and tissue regenerative eicosanoids, cytokines, and reactive oxygen species. The factors generate DNA mutations, cell damage, and epigenetic alterations leading to cellular transformation. In addition, the inflammation and oxidative stress leads to upregulated anti-apoptotic mechanisms, angiogenesis, and DNA damage but downregulated DNA repair, immune surveillance, and resolution. Together, these processes driven by carcinogen induced inflammation alter the microenvironment allowing for extracellular matrix remodeling, cytotoxicity and damage-associated molecular pattern (DAMP) signaling, and regenerative proliferation resulting in tumor growth.Fig. 3

7.3. Inflammation and DNA damage {#s0050}
--------------------------------

Inflammation generated from carcinogens, such as crystalline silica, can be a critical underlying mechanism promoting genotoxicity ([@bb0290]). Inflammation-induced cell proliferation potently stimulates carcinogen-induced mutations ([@bb1325]). These elegant studies demonstrate a key mechanism by which inflammation can act synergistically with DNA damage to induce mutations that drive cancer progression and cancer recurrence ([@bb1325]). Inflammation enhances the production of reactive chemical species that damage DNA which may stimulate mutations ([@bb1300]). Inflammation and cholangiocarcinoma (bile duct tumors) can be induced by NDMA combined with infections ([@bb2770]; [@bb2890]). Infection and NDMA-induced tumor tissue exhibit significantly higher numbers of inflammatory cells (especially eosinophils), bile duct proliferation, and IL-17+ cell infiltration compared to normal livers ([@bb2770]). NDMA activates the PI3K-Akt/PKB pathway in human neutrophils which activates pro-inflammatory transcription factors NF-κB, c-Jun, and FosB involved in nitric oxide (NO) production (through modulation of inducible nitric oxide synthase (iNOS) expression) ([@bb2080]). Thus, nitrosamines including NDMA stimulate inflammation via oxidative stress and an immune response ([@bb1035]). The association between N-nitroso precursors and esophageal cancer may be modified by inflammation ([@bb2115]). NDEA stimulates inflammatory cell infiltration (e.g. (lymphocytes, neutrophils, eosinophils, and Kupffer cells), pro-inflammatory cytokines, including the IL-1 and IL-6 signaling pathway, as well as oxidative stress and proliferation in the liver, stomach and colon including cyclooxygenase (COX-2) expression in hepatic tissues ([@bb0625]; [@bb0645]; [@bb1035]; [@bb1645]). Thus, inflammation plays a critical role in carcinogen-induced cancers.

Carcinogens such as NDMA also induce fibrosis leading to inflammation accompanied by the infiltration of lymphocytes, monocytes, granulocytes, and macrophages into the space of Disse ([@bb1355]). Activation of transcription factors including NF-κB, c-Jun, and FosB in inflammatory cells underlie NDMA-induced NO synthesis/release ([@bb2075]). N-nitrosamines are activated by inflammatory cells, such as macrophages ([@bb2300]). NDMA increases the proliferation of macrophages and expression of Raf in tumor-bearing lungs. Thus, the increase of both Raf and PCNA in the lung parenchyma surrounding NDMA-induced lung tumors suggesting an important lung tumor--macrophage interaction ([@bb2055]). IL-1β is also able to contribute to fibrosis while TNF-α increases anti-apoptotic signals to avoid cell death ([@bb0055]). Importantly, while carcinogens can induce inflammation, chronic inflammation can also increase carcinogen exposure and uptake within the body by weakening barrier functions ([@bb0890]).

7.4. Pro-inflammatory signaling {#s0055}
-------------------------------

Nuclear factor kappa B (NF-κB) is a transcription factor that plays a critical role in inflammation, cancer invasion, regulation of apoptosis, oxidative stress, tumor progression, and metastasis ([@bb1275]; [@bb1280]; [@bb2305]). NF-κB is activated by Toll-like receptors (TLR) signaling microbes, tissue damage, or primary cytokines and can trigger production of multiple pro-inflammatory cytokines, prostaglandin synthesis enzymes (including COX), nitric oxide (NO) synthase, angiogenic molecules, and other pro-tumorigenic mediators. STAT3/NF-κB signaling is important in cancer-related inflammation associated with IL-6-induced chronic inflammation ([@bb0505]). In addition to inflammation and oxidative stress, NF-κB plays a larger role in avoidance of apoptosis, which permits tumor cells to evade death while also allowing non-tumor cells to accumulate damaged cells, mutations, and increased compensatory proliferation ([@bb2855]). In a MYC transgenic model of hepatocellular carcinoma, deletion of NF-κB essential modulator (NEMO) from hepatocytes led to accelerated tumorigenesis but also switched the tumor phenotype from HCC to combined hepatocellular cholangiocarcinoma as NF-κB plays a modulatory role ([@bb1030]). PFOA can regulate MMPs (e.g. MMP2 and MMP9) release by regulating NF-κB phosphorylation levels ([@bb0520]; [@bb1735]). PFOA also induces the expression of the pro-tumorigenic molecules MMP2 and MMP9 via NF-κB in breast cancer cells ([@bb2930]). In a model of NDMA-induced esophageal carcinoma lyophilized black raspberries demonstrated anti-tumorigenic activity via the downregulation of NF-κB signaling leading to reduced oxidative stress markers and upregulation of antioxidant enzymes GPx and SOD ([@bb2310]). Chemopreventive activity of natural compounds, including flavonoids, in nitrosamine-induced hepatocarcinogenesis can lead to anti-inflammatory and antioxidant activity with reduction of MMP and VEGF angiogenic signals via NF-κB inhibition ([@bb0250]; [@bb1505]; [@bb2140]; [@bb2340]; [@bb2415]). In a NDEA-induced hepatocarcinogenesis model, deletion of IkB kinase Beta (IKKβ) activates NF-κB from hepatocytes demonstrating increased tumorigenesis via ROS production, JNK activation, and hepatocyte death. However, hepatocarcinogenesis was decreased with IKKβ deletion from hepatocytes and Kupffer cells via reduced compensatory proliferation of hepatocytes demonstrating not only the importance of NF-κB signaling and its reduction in tumor associated immune cells, but the importance of cellular crosstalk in carcinogen-induced cancers ([@bb1625]). Thus, NF-κB activation can mediate carcinogen-induced inflammatory cancers.

7.5. Pro-inflammatory cytokines {#s0060}
-------------------------------

Downstream signaling of NF-κB leads to chronic inflammation via upregulation of a series of pro-inflammatory cytokines and chemokines which promote carcinogenesis. Importantly, "cytokine storms" which are well established in infection (e.g. severe coronavirus (COVID-19) ([@bb0940]; [@bb1935]), are becoming appreciated in the setting of cancer therapy as immunotherapy and chemotherapy create an inflammatory tumor microenvironment via the release of a series of cytokines by immune cells ([@bb0740]; [@bb0825]). In a model of NMBA-induced esophageal tumorigenesis, deficiency of riboflavin increases pro-inflammatory cytokines, elevating levels of peripheral neutrophils and monocytes, as well as the oxidative stress marker 8-0HdG ([@bb1920]). In addition, NDMA increases gut permeability, which accelerates the entry of LPS into the blood stream. Activated Kupffer cells then produce several cytokines and growth factors such as TNF-α, TGF-β1, PDGF, and IL − 1β ([@bb0830]). These signaling molecules drive chronic inflammation with continued carcinogen exposure as the pro-inflammatory cytokines such as IL-1β, IL-6, IL-22, IFN-γ, and TNF-α further activate NF-κB and TGF-β generating a feedforward pro-tumorigenic inflammatory cycle ([@bb0830]). Further, co-exposure to AFB~1~ and FB~1~ increase carcinogenicity via upregulation of IL-10, IL-4, lipid peroxidation (LP), and caspase 3 ([@bb0005]). Anti-carcinogenic compounds, such as cordycepin, a component of a rare caterpillar fungus, demonstrated protective effects in NDEA-induced HCC via downregulation of pro-inflammatory cytokines IL-6, IL − 1β, IL-2, TNF-α and modulation of the PI3K-Akt-mTOR pathway ([@bb1310]; [@bb2910]). In an AOM/DSS model of colon carcinogenesis, an anti-cancer compound celastrol, reduces COX-2, TNF-α, IL-6, IL − 1β and iNOS ([@bb0180]). Another natural product, flaxseed, was able to reduce lung tumorigenesis in an NNK carcinogen-induced model affected Akt/JNK/MAPK signaling pathways to reduce the carcinogen-induced pro-inflammatory IL-6, IL-8 and increase the anti-inflammatory IL-12α ([@bb0455]). Demonstrating the importance of the pro-inflammatory cytokine TNF-α, TNF-α inhibition or deletion inhibits tumorigenesis in a NDEA-induced HCC model while reducing proliferation preventing activation of progenitor cells ([@bb1215]).

Other carcinogens such as asbestos have extensive changes on immune cells including expression of MMP7, CXCR5, CXCL13, and CD44 on exposed T cells and increased IL-6 initiating crosstalk between B and T cells with mesothelial and epithelial cells ([@bb1395]). Additionally, PFOA stimulates the production of critical pro-tumorigenic cytokines in multiple tissues including TNF-α, IL-1β and IL-6 in the liver or spleen, and increases proto-oncogenes (e.g. c-Myc activity in the spleen and thymus), which may be another important mechanism by which carcinogens cause cancer ([@bb2365]; [@bb2830]). PFOA may therefore impair the host-protective immune response. Carcinogen-induced immunotoxicity also occurs in other animals such as harbor porpoises living in oceans contaminated by persistent organic pollutants, polychlorinated biphenyls, and polybrominated diphenyl ether, resulting in impaired cellular responses from atrophy of the thymus and splenic depletion ([@bb0210]).

7.6. Eicosanoids {#s0065}
----------------

Products of arachidonic acid metabolism called eicosanoids, including prostaglandins, leukotrienes, lipoxins, and other cyclooxygenase or lipoxygenase products are potent regulators of inflammation, angiogenesis, and tissue homeostasis ([@bb0885]; [@bb1160]; [@bb2660]). Arachidonic acid is cleaved from the cell membrane by phospholipase 2 (PLA~2~) and other enzymes and when in the cytosol can be metabolized by 3 main branches: cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) enzymes. Studies on the arachidonic acid pathway initially focused on its role in inflammatory and cardiovascular diseases ([@bb1160]; [@bb2905]). Most recently**,** arachidonic acid-derived eicosanoids have attracted increasing attention due to the increasing evidence of their role in cancer biology ([@bb1150]; [@bb2425]). Besides epoxyeicosatrienoic acids (EETs), CYP also generate hydroxyeicosatrienoic acids (HETEs) ([@bb2905]) whose role in cancer biology is not as extensively characterized as the COX and LOX-derived eicosanoids ([@bb0915]; [@bb1785]).

Eicosanoid dysregulation can lead to chronic inflammation and oxidative stress or prevent pro-apoptotic signals generating the accumulation of damaged cells. The ratios of eicosanoids with opposing effects can be used to predict pathology following carcinogen exposure ([@bb1195]). Interestingly, NNK can interact with beta-adrenergic receptors to directly stimulate the release of arachidonic acid, which could lead to aberrant eicosanoid production ([@bb2205]). In addition to their roles in inflammation, the eicosanoid pathways also play a role in metabolism and bioactivation of carcinogens. CYP450 enzymes are also the main activators of many environmental carcinogens as they play a large role in drug and toxin metabolism. Interestingly, COX isoenzymes generate ROS and also may be responsible for bioactivation of multiple carcinogens via metabolism of aromatic and heterocyclic amines or polycyclic hydrocarbons which may account for the carcinogen specific activity of cyclooxygenases ([@bb2755]). Additionally, LOX is a peroxidase also generating ROS and free radicles may play an important role in the bioactivation of NNK via oxidation as the CYP450 enzymes were found to be only partially responsible for its activation ([@bb2360]).

The COX pathway leads to pro-tumorigenic and pro-inflammatory activity in multiple models, including carcinogen-induced cancers. COX-2 activation can sensitive tissues to genotoxic carcinogens ([@bb1805]). A tobacco carcinogen upregulates COX-1 expression correlated with NF-κB activation ([@bb2105]). Carcinogenesis of the skin upregulates COX-2 and prostanoid signaling but suppression of COX-2 and PGE~2~ synthase may have anti-tumorigenic effects ([@bb0575]; [@bb0690]). COX-2 was also demonstrated to stimulate tumorigenesis in a breast cancer model as COX-2 deletion reduced inflammation-associated carcinogenesis ([@bb1680]). NF-κB activation also increases colon carcinogenesis via upregulation of COX-2 leading to aberrant eicosanoid production ([@bb1490]). Interestingly, a flavonoid with anti-cancer properties regulates NDEA-induced carcinogenesis by downregulating COX-2/PGE~2~, as well as increasing antioxidants ([@bb2325]). However, the role of COX-2 may be context-dependent as COX-2 overexpression and upregulated prostaglandins can suppress tumorigenesis in skin ([@bb0280]). Moreover, COX-2 can also be host-protective by generating anti-inflammatory and pro-resolution lipid mediators from arachidonic acid including lipoxins and pro-resolution prostaglandins ([@bb0860]; [@bb1460]).

The lipoxygenase (LOX) pathways also play important roles in carcinogen-induced cancers via inflammation. Interestingly, ethanol stimulates carcinogenesis in a 4-NQO oral carcinogenesis model via induction of the 5-LOX pathway ([@bb0920]). Similarly, use of a 5-LOX inhibitor (garcinol) or herbal extracts (zyflamend) block LTB~4~ to exhibit chemopreventive activity in a DMBA-induced oral carcinogenesis model ([@bb0420]; [@bb2835]). Interestingly, cumin, a common spice used in curries, contained curcumin which inhibited TPA-induced skin inflammation by inhibiting the LOX metabolites 5-HETE and 8-HETE, as well as multiple prostaglandins ([@bb1120]). In an AOM/DSS model of colon inflammation-associated carcinogenesis, cysteinyl leukotriene receptor 1 (CysLT1R) deletion reduced pro-inflammatory cytokines leading to decreased leukocyte and macrophage infiltration via eicosanoid regulation ([@bb1910]). However, 15-lipoxygenase-1 (ALOX15) generates other lipid mediators which terminate inflammation, and downregulates NF-κB signaling, IL-6, IL − 1β, and TNF-α in AOM/DSS-induced colorectal cancer-associated inflammation ([@bb2505]). Zileuton, a 5-LOX inhibitor, is more potent in inhibiting DMBA oral carcinogenesis than celecoxib, a selective COX-2 inhibitor, via suppression of eicosanoids. A leukotriene A~4~ hydrolase (LTA~4~H) inhibitor suppresses carcinogenesis via eicosanoid regulation ([@bb2450]). However, as each of these eicosanoid pathways play key roles in carcinogen-associated inflammation, dual eicosanoid inhibition (e.g. dual COX-2/sEH inhibition) may exhibit more potent anti-tumor activity then targeting a single eicosanoid pathway ([@bb0760]; [@bb0825]; [@bb2930]). Supplementation of vitamin E or selenium in NMBA-exposed esophagus inhibited carcinogenesis via downregulation of both COX and LOX pathways inhibiting proliferation and angiogenesis ([@bb2815]).

In the context of arachidonic acid metabolism CYP450 enzymes generate monohydroxyeicosatrienoic acids (HETEs) and epoxyeicosatrienoic acids (EETs) ([@bb1940]; [@bb2905])^,^. CYP450-derived eicosanoids including EETs and epoxydocosapentaenoic acids (EDPs) play a key role in angiogenesis, tumor growth, and metastasis ([@bb1160]; [@bb1925]; [@bb2935]). Epoxygenated fatty acids (EpFA), eicosanoid metabolites generated by CYP450, were increased in the plasma and colon of azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced colon carcinogenesis ([@bb2695]). Generally, EETs, which are further metabolized into pro-inflammatory dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH), exhibit anti-inflammatory and pro-angiogenic activity ([@bb0825]; [@bb1925]; [@bb2990]). Analysis of patients with HCC demonstrated favorable survival prognostics with increased CYP4F2, CYP4F12, and CYP4V2 expression ([@bb0710]). Pharmacologic inhibition or genetic ablation of CYP monooxygenases, which generate epoxygenated fatty acids including EpOME, suppressed AOM/DSS-induced colon tumorigenesis ([@bb2695]). 2,3,7,8-tetrachlorodibenzop-dioxin, an environmental carcinogen, activates the aryl hydrocarbon receptor (AHR) transcription factor for CYP enzymes leading to dysregulated eicosanoid production ([@bb0605]). Importantly, following dioxin exposure these arachidonic acid metabolites were found in the heart of a chick embryo even though the heart lacks enzymes to metabolize arachidonic acid, suggesting systemic movement of eicosanoids may generate profound systemic and chronic effects ([@bb0605]).

7.7. Oxidative stress {#s0070}
---------------------

Oxidative stress results from an imbalance between production of free radicals and reactive oxygen or nitrogen species (RONS) and their elimination by through protective mechanisms, including antioxidants ([@bb2555]). Inflammation can stimulate tumor-promoting and tumor-initiating reactive chemical species, which can damage DNA leading to genetic instability, a hallmark of cancer, and oxidative stress. Oxidative and endoplasmic reticulum stress is often intertwined in inflammatory processes and is also induced by environmental carcinogens to promote tumor growth ([@bb0760]; [@bb1890]). The importance of oxidative stress is demonstrated via nongenotoxic carcinogens, such as dicyclanic hepatocarcinogenesis and arsenic, and their ability to induce DNA damage indirectly via increased ROS production, mitochondrial damage, upregulation of stress genes, and biomarkers such as 8-hydroxy-deoxyguanosine (8-OHdG) ([@bb1555]; [@bb1795]). Inflammation, including upregulation of COX-2, recruits leukocytes including neutrophils which can trigger oxidative damage, thus anti-inflammation can also prevent oxidative insult during tumorigenesis ([@bb1810]). Interestingly, neutrophils can also generate further production of N-nitroso carcinogens during intestinal inflammation promoting colon carcinogenesis ([@bb2600]). NDMA increases iNOS in neutrophils associated with carcinogenesis ([@bb2080]). Red meat, known to contain multiple carcinogenic compounds including nitrosamines, polycyclic aromatic hydrocarbons (PAHs), and heterocyclic aromatic amines (HAAs), increases the risk of human cancers via lipid peroxidation, inflammation, and generation of reactive oxygen species ([@bb2560]). N-nitroso compounds and their metabolism stimulate pro-inflammatory reactive oxygen species causing cellular injury ([@bb0025], [@bb0030]; [@bb0035]; [@bb0175]). Oxidative stress-induced cell injury plays a crucial role in NDEA-induced carcinogenesis as a single necrogenic dose of NDEA enhances levels of hepatic lipid peroxidation (LPO) and conjugated dienes as markers of oxidative stress ([@bb0170]).

The genotoxic activity of nitrosamine compounds such as NDMA can stimulate pathways of oxidative stress and inflammation leading to carcinogenesis ([@bb1035]). NDMA stimulates reactive oxygen species and induces toxicity including a dramatic change in the body weight of animals ([@bb2290]). The NDMA-induced genotoxic activity and DNA damage in cancer cells can be measured by DNA strand breaks and oxidative DNA damage induced by intracellular reactive oxygen species (ROS). ROS are an important mechanism for tumor promotion and oxidative stress. As a consequence of NDEA-induced oxidative and nitrosative DNA damage ([@bb1340]; [@bb2575]), inflammatory markers such as IL-1β and TNF-α are significantly elevated in liver, stomach and colon ([@bb1645]). The NDMA-mediated increase in NO production may also contribute to oxidative stress, a factor in the pathophysiology of numerous immune disorders. NO is a versatile regulator of numerous bodily processes and a major signaling molecule ([@bb2075]), while iNOS is found in various cells, including neutrophils ([@bb0205]; [@bb1660]). Thus, carcinogens could regulate immune cells and inflammation, in part, by affecting NO formation which may lead to modulated immune function.

Other carcinogen-induced processes, such as fibrosis, contribute to the vicious cycle of inflammation and oxidative stress during carcinogenesis ([@bb0015]; [@bb0830]). These processes lead to cellular injury and initiate inflammatory responses by releasing a variety of pro-inflammatory cytokines and growth factors that trigger activation and transformation of resting hepatic stellate cells into myofibroblast-like cells, which initiate increased synthesis of connective tissue proteins, especially collagens ([@bb0830]). NDMA-induced liver fibrosis results in the enhanced oxidative stress leading to the generation of oxyradicals which can bind to proteins and cellular constituents ([@bb0015]). Further, oxidative stress and ROS can lead to fibrosis and abnormal healing following injury which can lead to cellular transformation and carcinogenesis ([@bb0830]; [@bb0835]).

Many antioxidants exhibit anti-carcinogenic activity in experimental models. Antioxidants may be used for the prevention of arsenic-induced carcinogenesis, NDMA-induced hepatocellular carcinogenesis, and NDEA-induced esophageal carcinogenesis ([@bb1040]; [@bb2295]; [@bb2310]). Tocopherols, a form of vitamin E, have been suggested to have antioxidant properties, including ability to physically trap nitrogen species leading to protection in an AOM/DSS model of colon carcinogenesis ([@bb0175]; [@bb1250]; [@bb1405]; [@bb1425]). A flavonoid antioxidant, silymarin, inhibits a 4-NQO-induced tongue carcinogenesis model leading to increased apoptosis and decreased proliferation ([@bb2810]). Citral suppressed NDEA-induced HCC via inhibiting the suppression of antioxidants triggered by carcinogen exposure ([@bb1380]).

Nuclear factor erythroid 2-related factor 2 (Nrf2) is an important regulatory molecule of oxidative stress and a potential therapeutic agent in carcinogen-induced cancer. Inhibition of Nrf2 stimulates oxidative stress, inflammation, circulating cytokines, and proliferation leading to intestinal carcinogenesis ([@bb0435]). NDEA stimulates inflammatory and oxidative stress markers via COX-2 upregulation, yet ginger extract demonstrated protective effects via Nrf2 activation to suppress oxidation and inflammation ([@bb1645]). AFB~1~ upregulates Nrf2 signaling in response to oxidative stress, although expression of the SOD antioxidant is downregulated ([@bb2680]). In liver carcinogenesis Nrf2 activation as a result of AHR and CYP1B1 downregulation led to restoration of liver tissue and reduced oxidative damage ([@bb0295]). A novel compound, CDDO-Im, with anti-inflammatory properties also activates Nrf2 to potently inhibit AFB~1~-induced carcinogenesis in 100% of animals ([@bb0670]; [@bb1225]). A structurally similar compound in the family of synthetic pentacyclic oleanane triterpenoids, CDDO-Me is in clinical development. Further, a family of compounds with the same activity but simpler synthesis, tricyclic-*bis-*enone (TBE) compounds, is also potent in reducing oxidative stress to inhibit AFB~1~-induced carcinogenesis ([@bb1515]). Thus, inhibition of oxidative stress is a potent therapeutic approach to carcinogen-induced cancers.

Clinic inflammatory scores, including neutrophil to lymphocyte ratio or platelet to leukocyte ratio, can also predict cancer patient outcome ([@bb0610]; [@bb1015]; [@bb1535]; [@bb1950]; [@bb2945]). Pro-inflammatory cytokines such as IL-6 and IL-8 may be used to predict patient outcome for example in HCC patients undergoing transarterial chemoembolization ([@bb1585]). In an animal model of NDEA-induced HCC, the hepatic inflammation-fibrosis-cancer axis (IFC), including upregulation of TNF-α, IL-6, TGF-β1 and JAK2/STAT3 signaling, may predict carcinogen exposure after week 14--22 ([@bb0625]). The neutrophil/lymphocyte ratio (NLR) could be a prognostic predictor for urologic tumors, including kidney tumors. Interleukin-1β (IL-1β) and interleukin (IL-18) are products of activated inflammasomes that play central roles in innate immunity and inflammation. C-reactive protein (CRP), a prototypical pro-inflammatory cytokine and marker, may also be reflective of tumor progression through inflammation. An elevated serum level of CRP as an inflammation biomarker may portend a poor prognosis of cancer patients, including kidney and bladder cancer ([@bb0550]; [@bb1740]).

7.8. Cell death ("debris")-generated inflammation {#s0075}
-------------------------------------------------

Cancer therapy-generated tumor cell debris can stimulate tumor growth via a storm of pro-inflammatory cytokines and eicosanoids ([@bb0365]; [@bb0825]; [@bb2425]). Cellular debris (apoptotic cells) and inflammation-induced cellular damage can induce cellular proliferation to activate a "Phoenix Rising" Pathway) to promote wound healing and tissue regeneration of the damaged tissue ([@bb1475]). Cytotoxicity-induced pro-inflammatory activity of carcinogens and tissue damage/injury may lead to inflammation as a cancer co-initiator and predict low or negligible risk at noninflammatory carcinogen doses ([@bb0270]). Inflammation activated-stem cells involved in tissue repair in damaged tissue and may lead to cancer if the normal termination of inflammation is suppressed by mutations ([@bb0270]). Non-mutagenic cytotoxic agents such as alcohol, chloroform, and ultraviolet light induce cell death triggering cytokines which stimulate hyperplasia and tumor growth ([@bb0365]; [@bb0825]; [@bb2425]; [@bb2535]). While carcinogen-induced inflammation and oxidative stress can lead to cellular damage, cell death can play a complex role in carcinogenesis by either stimulating or inhibiting tumor growth ([@bb0285]; [@bb2425]). While cell death is beneficial to prevent accumulation of cells with accumulated DNA damage, it also generates stress signals leading to more inflammation and regenerative proliferation which can stimulate tumor growth. Carcinogens in tobacco smoke, including nicotine-derived nitrosamine ketone (NNK), trigger the IKKβ/JNK1 mediated apoptotic pathway leading to a subsequent proliferation response, while other carcinogens including aflatoxins trigger cell death via ROS production ([@bb2150]; [@bb2455]; [@bb2950]). Oxidative stress induced by carcinogens as nitric oxide induces cell death associated with COX-2 and PPARgamma signaling ([@bb1525]). In a naphthalene-induced nasal tumor model a dual mode of action links genotoxic and cytotoxic effects ([@bb0270]). Interestingly, in a NDEA-induced model of HCC, prevention of hepatocyte apoptotic pathways and inflammatory pathways inhibited carcinogenesis ([@bb2775]). Persistent apoptosis is a determinant for hepatocellular carcinoma, and lower rates of apoptosis via lower caspase 8 are associated with less aggressive disease ([@bb0265]).

As damage associated molecular patterns (DAMPs) released by dead cells generate inflammation, tissue injury and signal through NF-κB, the accumulation of these dead cells may promote carcinogenesis ([@bb1020]; [@bb1055]). Chemotherapy-generated apoptotic tumor cells ("tumor cell debris") stimulate macrophages to release a cytokine and eicosanoid storm promoting the chronic inflammatory environment during tumor growth ([@bb0365]; [@bb0825]; [@bb2425]). Tumor cells killed from chemotherapy or radiation, release soluble factors and extracellular vesicles, which can induce an immunosuppressive tumor microenvironment to trigger regenerative processes leading to increased proliferation of remaining tumor cells ([@bb1205]; [@bb1305]). Interestingly, NDEA-induced hepatocellular carcinoma was stimulated by NADPH oxidase 1 (NOX1) induction of pro-inflammatory cytokines including TNF-α and IL-6 via DAMPs released by dying hepatocytes demonstrating the importance of immune and non-immune cell crosstalk in carcinogenesis ([@bb1495]). In a study of three nongenotoxic carcinogens, cadmium chloride, methyl carbamate, and lithocholic acid, genome wide methylation analysis demonstrated changes in cancer and surveillance pathways, but also in autophagy pathways a mechanism by which the body clears damaged cells ([@bb1145]). Another nongenotoxic carcinogen, fumonisin B1, induces carcinogenesis via induction of apoptosis and necrosis leading to regenerative proliferation ([@bb0640]). NDMA-induced cytotoxic activity and apoptosis in various organs (e.g., large bowel) can lead to inflammation ([@bb2020]). In a liver model, NDMA-induced DNA adducts and cell necrosis were concentrated mainly in hepatocytes, suggesting the release of mitogenic stimuli to stimulate the proliferation of the cells ([@bb1440]).

Natural compounds, including rice bran, with anti-carcinogenic effects induce apoptosis and thus reduce the accumulation of mutated cells, but simultaneously inhibit inflammation and regenerative proliferation ([@bb0115]). Many environmental carcinogens dysregulate the cycles of cell death and proliferation by regulating pro- and anti-apoptotic proteins such as Bax, Bcl-2, caspases and other signaling cascades. Thiamethoxam-induced hepatocarcinogenesis not only stimulated oxidative stress and inflammation in rabbits, but upregulated anti-apoptotic proteins leading to transformed cell survival ([@bb0675]). An initiating hepatocarcinogenic dose of NDEA stimulated the apoptotic index via increased caspase-3 and Bax expression ([@bb1265]).

7.9. Dormancy escape {#s0080}
--------------------

Dormancy is a stage in cancer progression where the cancer cells are not dividing but survive in a quiescent state. Dormant tumors have been identified at autopsy in normal adults who died of trauma and without prior history or clinical evidence of cancer ([@bb0785]; [@bb0980]). The reported incidence of these dormant tumor cells has been as high as 39% for in situ breast carcinoma, 46% for in situ prostate cancer, and 36% for thyroid carcinoma ([@bb0260]). Thus, it is highly likely that many humans exposed to carcinogens already exhibit dormant tumors. These dormant tumors can act as a tumor initiator and promotion of tumor dormancy escape occurs when exposed to carcinogens. The trigger of dormancy escape, as numerous animal studies have shown, is typically of non-genetic nature and can include: wounding at a site near or distant from the site of the occult tumor, surgery, chemotherapy, radiation, biopsy, sustained inflammation, stimulated angiogenesis or the presence of non-mutagenic factors that perturb the metabolism of cells ([@bb1925]; [@bb1930]). Cell death can paradoxically trigger dormancy escape by the stimulation of pro-inflammatory and pro-angiogenic cytokines which suggests that cell death generated by carcinogens can stimulate tumor growth ([@bb0760]; [@bb0825]; [@bb2420]). In experimental models, tumor dormancy escape can occur by 90 days post-tumor cell injection of dormant tumor cells by the stimulation of angiogenesis ([@bb1925]).

7.10. Carcinogen-induced immunosuppression {#s0085}
------------------------------------------

A dysregulated immune system following carcinogen exposure can lead to chronic inflammation, but also immunosuppressive activity may further damage the host response to protect from cancer. Chronic inflammation, including signaling molecules such as PGE~2~, can lead to immunosuppression in the tumor microenvironment ([@bb2665], [@bb2670]). For example, pro-tumorigenic activity of NNK on alveolar macrophages modulated by PGE~2~ included immunosuppression ([@bb2480]). In a DMBA model of skin carcinogenesis, in xeroderma pigmentosa mice which are more susceptible, the carcinogen-induced not only pro-inflammatory mediators but also increased systemic immunosuppression ([@bb1760]). In an AOM/DSS model of colon carcinogenesis myeloid derived suppressor cells and their chemotaxis via CXCR2 promoted tumorigenesis via inhibition of CD8+ activity ([@bb1295]). Importantly, chronic exposure to carcinogens such as NDMA induce marked and persistent immunosuppression of cellular and humoral responses ([@bb0595]).

Carcinogens, including aflatoxins and tamoxifen, disrupt inflammation resolution and the innate immune system by impairing host-protective neutrophil and macrophage phagocytosis of debris ([@bb1605]; [@bb1640]; [@bb1705]; [@bb1775]). In addition, NDMA can negatively impact neutrophil phagocytic activity, oxygen metabolism, and functions associated with production and release of immunologically-active molecules ([@bb1185]), thus impairing inflammation resolution. NDMA is immunotoxic to immune cells, cell-mediated immunity and inflammation (e.g., mononuclear cells and neutrophils (PMN)) ([@bb1070]; [@bb1180]). Reduced host resistance to infectious agents (reduced response to streptococci and influenza challenge) following NDMA administration also indicate systemic toxicity on humoral immunity ([@bb2485]). NDMA also impairs the cellular immune response by altering the production and/or maturation/differentiation of bone marrow stem cells into functional macrophages ([@bb1815]; [@bb1820]; [@bb1825]).

Cytotoxic carcinogens can trigger cell death of lymphocytes leading to an immunosuppression without the ability to control the accumulating transformed cells ([@bb0120]; [@bb0405]). NDMA may impair the host immune response and exhibit immunotoxicity, including increased apoptosis (death) of leukocytes and production of pro-tumorigenic reactive oxygen species ([@bb1170]; [@bb1175]; [@bb1180]; [@bb1885]; [@bb2080]). PFOA also exhibits immunotoxic potential in mice ([@bb2365]). The toxic activity of NDMA greatly influences the biological activity and lifespan of immune cells ([@bb1170]), including neutrophils, by inducing a respiratory burst and subsequent release of ROS responsible for the apoptosis of these cells ([@bb1175]). NDMA can also modulate the apoptosis of human neutrophils by regulating the expression of death receptor DR5 as well as through the release of its soluble form (sDR5) ([@bb1185]). In a prospective clinical study the hepatocellular carcinoma tumor microenvironment exhibited pro-angiogenic and pro-inflammatory activity, but also a distinctly immunosuppressed environment including upregulation of PD-1, PD-L1 and FoxP3 regulatory immune cells in patients ([@bb0540]; [@bb1905]).

Carcinogens generate further immune suppressed environments through inhibition of the adaptive immune system. One of the primary cell targets of NDMA is the B-lymphocyte, thus likely reducing the overall reactivity of both T- and B-lymphocytes as exposure suppresses the IgM antibody-forming cell response to sheep red blood cells in a dose--dependent manner ([@bb1075]; [@bb1080]; [@bb2750]). NDMA depressed T-lymphocyte function as measured by T-cell proliferation in response to T-cell mitogens ([@bb1070]). NDMA suppresses T-cell-dependent antibody response ([@bb1200]). PFOA causes splenic and thymic atrophy with suppressed thymocyte proliferation ([@bb2845]). PFOA also inhibited CD4^+^CD8^+^ populations, demonstrating impaired splenocyte and thymocyte maturation from CD4^−^CD8^−^ to CD4^+^CD8^+^ cells ([@bb2365]). Normally, immune cells, such as T lymphocytes, secrete soluble factors (cytokines) that activate phagocytes to destroy the pathogens they have internalized ([@bb2840]). Furthermore, phagocytes utilize antibodies generated by B lymphocytes to allow them to recognize and destroy pathogens ([@bb0965]; [@bb2395]). Carcinogens such as aflatoxins generate tumor cell death ("debris") that can trigger tumor dormancy escape via an eicosanoid and cytokine storm of pro-inflammatory as well as pro-angiogenic mediators ([@bb0760]). Thus, carcinogen exposure may disrupt host-protective anti-tumor host immune responses and impair the resolution of inflammation.

8. Therapeutic approaches {#s0090}
=========================

8.1. Resolution and anti-inflammation are not equivalent {#s0095}
--------------------------------------------------------

Epidemiologic evidence suggests that the nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin reduces the risk and incidence of cancer ([@bb0850]; [@bb2660]). However, severe toxicity including bleeding has precluded the routine application of anti-inflammatory agents in the chemoprevention and treatment of cancer. Moreover, selective cytokine or eicosanoid blockade may not be sufficient to prevent carcinogen-induced cancers ([@bb0760]; [@bb0825]). Inflammatory transcription factors such as Nrf2 can reduce the DNA damage by neutralizing reactive chemicals with antioxidants and upregulating DNA repair pathways ([@bb1300]). The triterpenoid oleanane, a highly potent anti-inflammatory agent, prevents hepatocellular carcinoma (HCC) in an experimental rat model while only partially reducing AFB~1~-DNA adducts ([@bb1225]). Other anti-inflammatory mechanisms designed to reduce cancer risk include a healthy diet, exercise, antioxidants, and spices (e.g. curcumin).

A new potentially-paradigm shifting direction of inflammation research has emerged with the discovery of the autacoid superfamily of specialized pro-resolving lipid autacoid mediators (SPMs), including resolvins, maresins, protectins, and lipoxins, as key mediators in the resolution of inflammation, possessing potent inflammation clearing activity without being immunosuppressive ([@bb1800]; [@bb2250]; [@bb2255]; [@bb2265]). The resolution of inflammation is now appreciated to be an active process regulated by SPMs, which are endogenously produced in multiple tissues throughout the human body ([@bb2260]). Pro-resolution mediators resolvins may have a dual function in cancer associated-inflammation: inhibiting the pro-inflammation activities of pro-inflammatory cytokines while activating macrophages to phagocytize tumor-promoting cellular debris, thereby preventing chronic inflammation that stimulates tumor growth. Targeting endogenous lipid autacoid mediators such as lipoxins and resolvins offers an entirely new approach to cancer therapy via cell autonomous and non-cell autonomous mechanisms in the tumor microenvironment ([@bb0125]; [@bb0850]; [@bb1390]; [@bb1595]; [@bb1930]; [@bb2280]; [@bb2425]; [@bb2435]; [@bb2875]; [@bb3025]).

8.2. Cyclooxygenase (COX) inhibition {#s0100}
------------------------------------

Selective COX-2 inhibitors (coxibs) and nonselective NSAIDs can reduce the incidence of cancers in humans and in experimental models ([@bb2660]). The risk for colorectal cancer is increased in patients with inflammatory bowel disease. COX-2 and PGD~2~ have been identified as potential therapeutic targets for the chemoprevention of colon cancer ([@bb2660]). However, COX-2 is also a pivotal enzyme necessary to stimulate the resolution of inflammation and production of specialized pro-resolving mediators (SPMs) such as lipoxins ([@bb2635]). Given the important roles of COX-2 (in part through biosynthesis of PGD~2~) in the resolution of inflammation, inhibition of COX-2 may be "resolution toxic" ([@bb0865]; [@bb1930]; [@bb2260]). Inflammation (e.g. paw swelling) in COX-2 KO mice failed to resolve and exhibited significant leukocyte infiltration. COX-2 is an important source of PGD~2~ (15-deoxy-Δ^12-14^PGJ~2~) and is also essential for driving resolution of the inflammatory response in the lung ([@bb0865]). Human fibroblasts generate pro-resolving peroxisome proliferator-activated receptor-γ ligands in a COX-2-dependent manner via pro-resolving prostaglandins ([@bb1400]). Thus, inhibition of COX-2 impairs resolution of inflammation because prostaglandins such as PGE~2~ initiate a lipid mediator class switching to SPMs such as lipoxins to accelerate the resolution of inflammation ([@bb1460]).

8.3. Nonsteroidal anti-inflammatory drugs (NSAIDs) {#s0105}
--------------------------------------------------

Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for inflammatory diseases, pain, fever and include aspirin, celecoxib, ibuprofen, sulindac, diclofenac, and ketorolac ([@bb2660]). NSAIDs that block the enzymatic activity of COX and subsequent production of prostaglandins, are widely used to treat inflammation and pain ([@bb1690]) and exhibit anti-cancer activity ([@bb0085]; [@bb0850]; [@bb1130]). However, the adverse side effects of NSAIDs such as bleeding prevent their chronic use at high doses ([@bb2660]). Certain NSAIDs are selective COX-1 and/or COX-2 inhibitors. Aspirin exhibits anti-cancer activity by inhibiting inflammation and triggering the resolution of inflammation ([@bb0850]; [@bb2315]; [@bb2660]). NSAIDs inhibit angiogenesis, including suppressing carcinogen-induced angiogenic signaling of cytokines, NF-κB, MMP-2 and MMP-9 in colon cancer progression ([@bb2585]).

The NSAID sulindac can prevent carcinogen-induced intrahepatic cholangiocarcinoma in experimental models ([@bb2735]). The loss of 15-hydroxyprostaglandin dehydrogenase, a prostaglandin-degrading enzyme that inhibits COX-2, stimulate tumor growth. However, sulindac, but not aspirin or celecoxib, overcomes the low 15-PGDH expression to reduce AOM-induced colon carcinogenesis demonstrating a difference in anti-tumor activity with various NSAIDs ([@bb0745]). Sulindac partially inhibits NDEA-induced HCC, although statins exhibit more potent anti-inflammatory and anti-cancer activity ([@bb0135]). AFB~1~ upregulates COX-2 which activates the inflammasome leading to tumor-promoting inflammation. In contrast, celecoxib reduced this inflammation demonstrating the regulation of inflammation by eicosanoids and inflammatory mediators ([@bb2960]). Additionally, etodolac, a COX-2 inhibitor, suppresses *N*-nitrosobis(2-oxopropyl)amine (BoP)-induced experimental biliary carcinogenesis ([@bb2550]).

While initial studies have focused on colorectal cancers, low-dose aspirin exhibits anti-tumor activity in other tumor-types, including lung, breast, prostate, and metastatic cancers ([@bb2660]). Aspirin can stimulate resolution by triggering the biosynthesis of resolvins, lipoxins and protectins ([@bb0850]; [@bb2230]). Compelling evidence of aspirin\'s anti-cancer activity stems from patients receiving low-dose aspirin for cardioprevention, in which a substantial fraction (20--30%) benefits from a decrease in cancer incidence. Importantly, the use of low-dose aspirin in cancer patients is limited by adverse side effects, such as gastrointestinal bleeding and hemorrhagic stroke, that necessitate hospitalization ([@bb0850]). Aspirin-triggered resolvins and lipoxins may account for aspirin\'s anti-tumor activity at least in part without the toxicity of aspirin ([@bb0480]; [@bb0850]). Because SPMs are not triggered by other NSAIDs besides aspirin, this may explain why aspirin\'s beneficial anti-tumor activity has not been fully recapitulated with other NSAIDs ([@bb0850]).

However, NSAIDs can down-regulate pro-tumorigenic cytokines but also generate toxic side effects and may be immunosuppressive resulting in increased risk for infections. Pre-treatment of the NSAID carprofen impaired initiation of inflammatory- and overlapping resolution response and promoted cardiorenal syndrome and heart failure ([@bb1385]). The classic cyclooxygenase inhibitors, celecoxib and indomethacin, that block thromboxanes and prostanoids do not inhibit production of the clot-driven SPM cluster ([@bb1880]). Additionally, NSAIDs have been associated with gastrointestinal (GI) injury for a century ([@bb2660]). It was the discovery by Vane in 1971 that these drugs suppress the biosynthesis of prostaglandins (PGs) that first suggested that autacoids may play a role in the maintenance of GI mucosal injury ([@bb2595]). Coadministration of a selective COX-2 inhibitor with aspirin inhibits pro-resolution lipoxin synthesis in the stomach increasing gastric mucosal damage ([@bb0755]). Administration of synthetic LXA~4~ prior to aspirin resulted in a dose-dependent reduction in the extent of gastric damage. Thus, aspirin-triggered lipoxins reduce injury to the gastric mucosa ([@bb2640]).

Standard anti-inflammatories such as steroids, NSAIDs, COX-2 inhibitors, and cytokine antagonists do not clear debris and may be "resolution toxic" ([@bb0865]; [@bb1930]; [@bb2230]). For example, in a model of CCL4-induced liver fibrosis and inflammation the use of celecoxib reduced PGE~2~ levels which was not sufficient to inhibit the liver injury and inflammation ([@bb0985]). Acetaminophen and indomethacin also generate 18-HEPE production, whereas selective cyclooxygenase-2 (COX-2) inhibitors block 18-HEPE production ([@bb2260]). Both 18-HEPE and RvE1 are anti-inflammatory, stopping leukocyte migration and stimulating resolution of inflammation. NSAIDs and COX-2-inhibitors impair inflammation resolution, efferocytosis, and neutralize PGE~2~ and PGD~2~-induced class switching to SPMs. Other "resolution toxic" drugs including lipoxygenase (LOX) inhibitors as 5-LOX plays a critical role in the biosynthesis of two classes of SPMs, lipoxins and resolvins. Lidocaine impairs resolution by inhibiting efferocytosis ([@bb2260]). In contrast, frequently used drugs such as aspirin promote resolution through acetylation of COX-2, and triggering production of R-epimer lipoxins, resolvins, and protectins. Statins also boost SPMs and the resolution of inflammation ([@bb2230]). Glucocorticoids can have mixed activity regarding resolution of inflammation by increasing the pro-resolving annexin A and efferocytosis but are immunosuppressive ([@bb2180]). Dexamethasone can stimulate SPM production to stimulate resolution of airway inflammation as well as macrophage phagocytosis of apoptotic cells ([@bb1615]; [@bb2045]).

While PGE~2~ and LTB~4~ initiate inflammation following tissue injury, PGD~2~ is a pro-resolution prostaglandin that triggers the switch from initiation of inflammation to resolution by inducing 15-LOX and SPM production which is upregulated in colitis patients who undergo long term remission ([@bb2230]; [@bb2625]). Thus, pro-resolution prostaglandins inhibit IKKβ to suppress NF-κB induced chronic inflammation, may be a therapeutic approach to carcinogen-induced inflammation ([@bb2125]). Alternatively, more specific inhibition of microsomal PGE synthase (mPGES-1) suppressed carcinogen-induced colon cancer without broadly blocking prostaglandin signaling as a potential mechanism to reduce NSAID-associated toxicity ([@bb1830]). Thus, inhibition of eicosanoid enzyme pathways may disrupt inflammation resolution in carcinogen-induced cancers which can be restored via supplementation of pro-resolution lipid mediators.

8.4. Specialized Pro-resolving Mediators (SPMs) {#s0110}
-----------------------------------------------

A paradigm shift is emerging in our understanding of the resolution of inflammation as an active biochemical process with the discovery of novel endogenous specialized pro-resolving lipid autacoid mediators (SPMs), such as resolvins, lipoxins, protectins and maresins ([@bb2230]). Resolvins and other pro-resolution lipid mediators stimulate macrophage-mediated clearance of cellular debris and counter pro-inflammatory cytokine production, a process called inflammation resolution. Resolution indices utilized temporal lipidomics, proteomics, and flow cytometry to establish relationships between cell trafficking, eicosanoids, pro-resolving lipid mediators and chemokines/cytokines ([@bb0165]; [@bb2210]). Tumor-associated macrophages (TAM) family members (TYRO3, AXL and MerTK) play important roles in the resolution of inflammation in many diseases including infections and cancer via efferocytosis ([@bb0650]). MerTK signaling also has an important role in the resolution of inflammation by stimulating production of SPMs, including lipoxin A~4~ (LXA~4~) and RvD1 ([@bb0315]). MerTK-deficient mice exhibit impaired phagocytosis of apoptotic cells contributing to development of allergic inflammation([@bb0725]), atherosclerosis ([@bb2490]), or autoimmune diseases ([@bb2130]).

SPMs (e.g. resolvins, protectins, and maresins) are biosynthesized from omega-3 fatty acids EPA and DHA and consist of families including resolvins (D and E series), maresins and their conjugates in tissue repair, protectins, and arachidonic acid-derived eicosanoid lipoxins ([@bb2260]). SPMs function via G protein coupled receptors including GPR32, GPR18, ChemR23, GPR37, and LGR6 have been identified for RvD1, RvD2, RvE1, PD1, and Mar 1, respectively ([@bb0155]; [@bb0440]; [@bb0450]; [@bb1375]; [@bb1895]). In a metabololipidomics LC-MS/MS analysis screening included products of the DHA-derived bioactive metabolome (resolvins of the D series, maresins, protectins), EPA-derived bioactive metabolome (lipoxins, resolvins of the E series), and AA-derived mediators (lipoxins, leukotrienes, prostanoids) all of which regulate specific inflammatory disease processes. SPMs function potently in other inflammatory diseases including reducing thrombosis ([@bb0430]). SPMs inhibit the recruitment of neutrophils that produce DNA damaging oxygen radicals, which may inhibit the carcinogen-induced inflammation promoting oxidative damage and mutagenesis. Limiting neutrophil tissue damage may also inhibit regenerative proliferation triggered as an injury response. SPMs, including protectins such as protectin DX, can reduce the production of reactive oxygen species and downregulate the activity of COX-2 in neutrophils ([@bb1550]). Notably, electrical stimulation of the vagus nerve is an alternate approach to stimulate the local production of SPMs while reducing prostaglandins and leukotrienes ([@bb2245]).

Lipoxins are the first SPMs discovered although it took a long time to uncover their role in resolution of inflammation as potent, active stop signals for immune cell (e.g. neutrophil) infiltration and are biosynthesized from arachidonic acid ([@bb2250]). Lipoxins (LX) are trihydroxytetraene-containing eicosanoids typically generated through transcellular biosynthetic pathways involving either 5- and 15-lipoxygenases (LOX) or 5- and 12-LOX. Lipoxins are produced relatively early during resolution of self-limited acute inflammatory responses ([@bb2230]). Lipoxins are biosynthesized by immune cells such as neutrophils and macrophages in response to stresses such as inflammatory stimuli, injury, or infection. Endogenous lipoxins are the only arachidonic acid-derived SPM, and act as antagonists of pro-inflammatory and pro-tumorigenic leukotrienes. The Serhan laboratory utilized lipid mediator metabololipidomics, proteomics (liquid chromatography--tandem mass spectrometry \[LC-MS/MS\]), and cell trafficking in self-limited exudates to identify three more new families of pro-resolving mediators, termed the "resolvins" (short for resolution phase interaction products), "protectins," and "maresins" (short for macrophage mediators in resolving inflammation) ([@bb1800]; [@bb2255]; [@bb2265]). Each family is structurally distinct and biosynthesized from essential fatty acid precursors eicosapentaenoic acid (EPA), docosapentaenoic acid (n-3DPA), or docosahexaenoic acid (DHA).

Aspirin stimulates the biosynthesis aspirin-triggered specialized pro-resolving mediators (AT-SPMs) from omega-3 polyunsaturated fatty acid substrates, including eicosapentaenoic acid (EPA) and docohexaenoic acid (DHA) by acetylation of COX-2 ([@bb2255]). AT-SPMs include endogenous production of aspirin-triggered lipoxins, aspirin-triggered resolvins and aspirin-triggered neuroprotectins ([@bb0475]; [@bb0480]; [@bb1965]; [@bb2230]; [@bb2240]; [@bb2460]). Stable analogues of lipoxin A~4,~ lipoxin B~4,~ and aspirin-triggered lipoxin A~4~ inhibit neutrophil infiltration more potently than aspirin and rescue resolution deficits in various inflamed tissue injury models ([@bb0490]; [@bb2210]; [@bb2220]; [@bb2465]). Aspirin-triggered resolvin D3 are potent immunoresolvents, including blocking neutrophil transmigration as well as stimulating macrophage phagocytosis and efferocytosis ([@bb0565]). Aspirin-triggered resolvins can mediate the anti-proliferative and anti-tumor activity of aspirin ([@bb0475]; [@bb0850]). Aspirin-triggered resolvins can mediate the anti-tumor activity of aspirin at \>10,000 fold lower doses than aspirin without toxicity in experimental cancer models via resolution of inflammation ([@bb0850]). Preoperative administration of the NSAID ketorolac and/or resolvins (RvD2, RvD3, and RvD4) activate endogenous resolution programs before surgery to eliminate micrometastases and reduce tumor recurrence ([@bb1930]).

Importantly, as NF-κB is central to inducing tissue injury and inflammation in carcinogenesis, SPMs have been shown to downregulate this signaling via activation of NF-κB regulators, including 15-epi-lipoxin A~4~ induction of A20 and SIGIRR via its ALX/FPR2 receptor signaling following LPS-induced inflammation ([@bb2275]). Resolvin D1 protects from LPS-induced inflammation in a lung injury model via inhibition of damaging oxidative stress ([@bb2690]). Upregulation of the ALOX-15/LXA4 pathway in a PMA-induced skin inflammation model can promote the resolution of inflammation via inhibition of IFN-γ ([@bb2925]). Resolvin D1 in colitis-associated cancer inhibits c-Myc and TNF-α in colon cancer cells ([@bb3025]). In an inflammatory intestinal model, protectin D1~n-3DPA~ and resolvin D5~n-3DPA~ protected against colitis and intestinal injury, both of which are risk factors for intestinal carcinogenesis ([@bb0875]).

An important function of pro-resolution mediators or signaling pathways is the induction of macrophage phagocytosis and efferocytosis. Clearance of microbes as well as apoptotic cells is important in multiple inflammatory diseases, including carcinogen-induced cancers as dead cells or increased microbe uptake can stimulate chronic inflammatory cycles. Peroxisome proliferator-activated receptors (PPARs) stimulate macrophage phagocytosis to promote clearance of infection and inhibit pro-inflammatory mediators in macrophages, which may be key to "resolve" inflammation-driven cancers ([@bb0655]; [@bb1945]). As targeting specific macrophage phenotypes is crucial to the resolution of inflammation in carcinogen-induced cancers, a MerTK macrophage phenotype has been demonstrated to induce phagocytosis and prevent liver damage ([@bb2525]). Additionally, LTB~4~, a potently pro-inflammatory mediator, can be detected via PPAR-α binding which signals for its metabolism and clearance in the liver to control pro-inflammatory signaling ([@bb0600]). Thus, exploring multiple targets involved in the resolution of inflammation may elucidate novel therapeutics in carcinogen-induced inflammation and cancer.

SPMs also induce a macrophage phenotype switch from a generally M1 to M2 phenotype which promotes efferocytosis and phagocytosis functions ([@bb2745]). Hypoxia activates resolution metabolomes (SPM-biosynthetic circuits) which stimulate resolution including resolvins in M2-like human macrophages via interactions with erythrocytes which store omega-3 fatty acids to increase phagocytosis and efferocytosis ([@bb1875]). This clearance of dead and damaged cells would inhibit the increased inflammatory response to DAMPs and reduce the debris-induced macrophage-derived cytokine storm. SPMs, including resolvins, have functioned to clear therapy-generated dead cells to prevent their generation of tumor promoting inflammation, as well as prevent micrometastases to prolong survival in surgery-stimulated tumor dormancy escape models ([@bb1930]; [@bb2425]). In addition, phagocytosis of inflammatory microbes which may have increased in the tissue via carcinogen exposure and failed barrier function may prevent synergistic tumorigenic inflammation. Macrophage phenotype is of utmost importance in the tumor microenvironment, as M1-like macrophages produce prostaglandins and leukotrienes generating an inflammatory and pro-tumorigenic microenvironment, while M2-like macrophages translocate 5-LOX and 15-LOX-1 to produce resolvins and maresins in response to inflammatory bacteria stimuli ([@bb2745]).

A critical difference between pro-resolution mediators ("resolving" inflammation) compared to anti-inflammation ("blocking" inflammation) is that while most anti-inflammatory agents can lead eventually to immunosuppression, the resolution of inflammation in an active endogenous reprogramming of the immune response to turn off inflammation without being immunosuppressive. In surgery-stimulated and chemotherapy-stimulated cancer models preoperative stimulation of inflammation resolution via resolvins (RvD2, RvD3, and RvD4) inhibited metastases and induced T cell responses ([@bb1930]). SPMs also promote the differentiation of B cells to be antibody-producing thus endogenously enhancing the adaptive immune system ([@bb2060]). SPMs not only inhibit macrophage-derived pro-inflammatory cytokines but prevent activated CD8+ and CD4+ cells from releasing inflammatory cytokines without inhibiting T regulatory cells ([@bb0070]; [@bb0075]). Thus, the resolution of inflammation via SPMs may be a novel approach to preventing carcinogen-induced cancers via downregulation of pro-inflammatory cytokines, suppression of neutrophil infiltration, reduced oxidative damage, and clearance of carcinogen-generated debris ([Fig. 4](#f0020){ref-type="fig"} ).Fig. 4Inflammation resolution in carcinogen-induced cancer.Carcinogen (NDEA) induced inflammation causes tissue damage and cell death of normal cells (hepatocytes) generating cellular debris. These dead cells activate local macrophages (Kupffer cells) to a pro-inflammatory phenotype generating a cytokine storm. This chronic inflammation reduces pro-resolving mediators including SPMs and EETs and signals for angiogenesis, fibrosis, and inflammatory cell infiltration. Infiltrating white blood cells add to the tissue injury by producing reactive oxygen and nitrogen species triggering the upregulation of NF-κB, COX-2, 5-LOX, and MMPs in surrounding hepatocytes generating a vicious cycle leading to tumor growth. However, resolution of inflammation via SPMs or sEH inhibition may break this pro-tumorigenic cycle. Resolution promotes macrophage phagocytosis of cellular debris, inhibits the cytokine storm, suppresses inflammatory infiltration, and is not immunosuppressive leading to the downregulation of NF-κB, COX-2, 5-LOX, and MMPs and inhibition of carcinogenesis.Fig. 4

8.5. Lipoxins {#s0115}
-------------

The most extensively studied SPMs in cancer biology at this time are the lipoxins (e.g. LXA~4~). Lipoxins suppress cancer cell proliferation in culture and in animal xenograft models inhibit tumor cell invasion ([@bb0425]; [@bb0475]; [@bb2200]; [@bb3035]). Lipoxins exhibit anti-inflammatory actions by inhibiting NF-κB signaling pathway ([@bb0845]). Lipoxins inhibit pro-inflammatory cytokines (IL-8) and adhesion molecule (i.e., ICAM-1) expression in human astrocytoma brain tumor cells ([@bb0580]). LXA~4~ potently inhibits the leukocyte trafficking to the inflammatory site and stimulates the phagocytosis of apoptotic cells by tissue macrophages ([@bb0095]; [@bb0425]). ATL-1, a synthetic analogue of 15-epi-lipoxin A~4~, inhibited melanoma tumor progression via switching tumor associated macrophages (TAM) from an M2- to an M1-cytotoxic like profile, promoting inhibitory activity on tumor cell proliferation and survival, and triggering tumor cell apoptosis ([@bb2335]). LXA~4~ can inhibit MAPK signaling to suppress aberrant COX-2 expression induced by IL-1β signaling in endometriosis, an inflammatory risk factor for endometrial cancer ([@bb0555]). However, ATL-1 had no direct effect on cancer cell proliferation ([@bb2335]). Additionally, LXA~4~ did not exert any direct anti-proliferative effect on liver cancer (H22 cells) ([@bb0425]).

Cancer progression including leukemia and colorectal cancer is associated with down-regulation of lipoxins ([@bb1545]; [@bb2400]). Downregulation of lipoxin A~4~ (LXA~4~) plays a role in Kaposi\'s sarcoma (KS)-associated herpesvirus (KSHV) infection pathogenesis and KS-related cancer ([@bb0360]). Serum LXA~4~ levels were decreased in colorectal cancer patients and specifically in the tumor tissue, while cancer patients expressed higher serum levels of LTB~4~, IL-1β, IL-6, CXCL8, TNF-⍺, and CCL2. LXA~4~ suppresses the colorectal tumor levels of pro-inflammatory mediators IL-1β, IL-6, TNF-⍺ and LTB~4~ while up-regulating anti-inflammatory IL-10 expression ([@bb1545]). LXA~4~ also inhibited the infiltration of CD45+ leukocytes and CD68+ macrophages in the colorectal tumor tissue. LXA~4~ suppresses the expressions of p-ERK, p-P38 and NF-κB in the xenograft, inhibit the proliferation and migration of colorectal cancer cells stimulated by activated macrophage-conditioned media ([@bb1545]). Kaposi\'s sarcoma (KS) occurs is frequently identified in HIV infected patients ([@bb0360]). The lipoxin receptor ALX/FPR was expressed on human KS tissue sections ([@bb0360]). Treating KS-IMM cells with lipoxins (LXA~4~ or 15-epi-LXA~4~) reduced the levels of pro-inflammatory cytokines IL-6 and IL-8, enzymes COX-2, 5-LO, and their metabolites ([@bb1675]).

Lipoxins and their analogues are potent inhibit tumor growth including hepatocellular carcinoma, melanoma, and Kaposi\'s sarcoma by suppressing angiogenesis such as endothelial cell proliferation, endothelial cell migration, VEGFA-induced angiogenesis, VEGF-induced permeability, VEGF-stimulated VEGFR2 (KDR/FLK-1) phosphorylation, COX-2, 5-LO, PGE~2~ and LTB~4~ ([@bb0130]; [@bb0350]; [@bb0425]; [@bb0735]; [@bb0975]; [@bb1210]; [@bb1675]; [@bb2335]; [@bb2605]). LXA~4~ inhibits VEGF and HIF-1α production by H22 hepatocellular carcinoma tumor cells in a dose-dependent manner ([@bb0425]). The lipoxin analogue BML-111 inhibited serum VEGF production in vivo in H-22 tumor bearing mice ([@bb0425]). In murine hepatocarcinoma, melanoma and CRC xenograft models, LXA~4~ suppressed tumor growth by targeting regulatory B cells (Bregs) through the inhibition of important signaling pathways ([@bb2715]). Bregs inhibit functions of CD8^+^ cytotoxic T cell in the tumor microenvironment. Thus, LXA~4~ may induce sustained anti-tumor immunity favoring the CD8^+^ T cell response. Lipoxin metabolically stable analogs may protect from tumor extravasation by inhibiting VEGF-induced endothelial permeability ([@bb2605]).

SPMs also exhibit cell-autonomous activity on cancer cells, independent from their anti-inflammatory action. In a murine model of liver cancer, LXA~4~ inhibits hepatocarcinoma tumor growth by regulating the induction of MDSCs in response to T-reg depletion and inhibiting tumor angiogenesis ([@bb0425]; [@bb2915]). LXA~4~ also suppresses acute myeloid leukemia cell migration and stimulates the phagocytic clearance of apoptotic cells by all-trans retinoic acid (ATRA)-treated alveolar macrophages ([@bb2545]). Interestingly, LXA~4~ shares structural similarities with estrogen 17-estradiol and possesses anti-estrogenic activity by competing for estrogen receptors, suggesting a potential effect in estrogen-associated diseases, such as endometrial cancer ([@bb0330]).

Lipoxin A~4~ as an endogenous lipid mediator can reprogram the tumor stroma to target pancreatic and liver cancer. LXA~4~ inhibited pancreatic cancer cell invasion by inhibiting the reactive oxygen species as well as MMP9 and MMP2 ([@bb3050]). In patients with pancreatic cancer, a low Lipoxin effect score (LES) has been observed. Specifically, a low LES tended to correlate with lymph node and distant metastasis. The "Lipoxin effect score" (LES) was the product of the immunohistochemistry scores of both 15-LOX and FPRL1. LES was correlated with aggressive metastatic potential in pancreatic tissue from pancreatic cancer patients ([@bb3045]). In PDAC, human pancreatic stellate cells (hPSCs), the main precursors of pancreatic cancer associated fibroblasts (CAFs), become activated and induce fibrosis by secreting extracellular matrix, which presents a barrier to anti-cancer drugs ([@bb2195]). Lipoxin A~4~ can disrupt the pro-tumoral paracrine signaling of human (hPSCs) ([@bb2195]). LXA~4~ inhibited the activation of hPSCs into CAF-like myofibroblasts in vitro and inhibited hPSC-induced tumor-promoting activity ([@bb2195]). LXA~4~ can also inhibit renal and lung fibrosis ([@bb1755]; [@bb2110]). Lipoxin A~4~ also inhibited pancreatic tumor growth via anti-fibrotic mechanisms such as reduced collagen I expression and thus may increase the efficacy of chemotherapy and radiation in pancreatic cancer ([@bb2195]). LXA~4~ also reduced tumor angiogenesis as determined by a reduction in the endothelial marker CD31 ([@bb2195]). In a liver metastasis model in nude mice, the LXA~4~ analogue mimetic BML-111, could inhibit the metastasis of pancreatic cancer cells ([@bb3045]). Lipoxin reverses mesenchymal phenotypes to attenuate invasion and metastasis via inhibition of autocrine TGF-β1 signaling in pancreatic cancer ([@bb3045]). EMT is a metastasis-promoting process in which cancer cells lose epithelial phenotypes such as E-cadherin expression and acquire mesenchymal characteristics including elevated expression of N-cadherin and vimentin expression ([@bb3045]).

Aspirin-triggered-lipoxin, 15-epi-LXA~4~ analog, is a potent inhibitor of endothelial cell responses and angiogenesis in vitro and in vivo. Lipoxin and AT-LXA~4~ treatment of a cancer-induced bone pain model results in suppression of spinal pro-inflammatory cytokines including IL-1 and TNF-⍺ ([@bb1110]). LXA~4~ administration also promoted the regression of DMBA/TPA-- induced papillomas and reduced several pro-inflammatory cytokines including IFN-gamma in papilloma tissue ([@bb2655]). IFN-gamma maintains inflammation and papilloma growth by repressing LXA~4~, demonstrating a dynamic balance between pro-inflammatory factors and pro-resolution lipid mediators ([@bb2655]). Lipoxins promote resolution of inflammation increasing papilloma regression independent of upregulating IFN-gamma by enhancing anti-tumor immunity. Thus, lipoxins are a potential treatment for papillomas and other cancer types.

8.6. Resolvins {#s0120}
--------------

SPMs such as resolvins are entirely unique from traditional anti-inflammatory agents in that they actively promote resolution of inflammation via activation of macrophages to clear inflammatory cell debris and killing/clearing microbes, counter-regulate pro-inflammatory cytokines, and halt leukocyte infiltration to reduce the propagation of inflammation at pico-nanogram concentrations ([@bb2230]). Reduced resolvins have already proven to be critically involved in a number of autoimmune diseases characterized by uncontrolled inflammation ([@bb2230]; [@bb2260]). Resolvins are highly effective in treating diseases driven by excessive inflammation at picogram levels in vivo (logs lower than aspirin or dexamethasone) in a wide variety of experimental pre-clinical models of inflammatory diseases([@bb0070]; [@bb0100]; [@bb0160]; [@bb0215]; [@bb0510]; [@bb0660]; [@bb0880]; [@bb0970]; [@bb0990]; [@bb0995]; [@bb1010]; [@bb1095]; [@bb1210]; [@bb1290]; [@bb1730]; [@bb2255]; [@bb2385]; [@bb2500]; [@bb2590]). Clinical trials show increasing resolvin activity in inflammatory diseases such as dry eye inflammation and periodontal diseases can reduce local inflammation ([@bb2260]).

Demonstrating the importance of resolvins in cancer, the neutralization of Resolvin D1 receptor GPR32-mimics FPR1-silencing which increases angiogenesis and tumorigenesis of gastric cancer cells ([@bb2035]). Formyl peptide receptors (FPR1, 2, and 3) are pattern recognition receptors of the G-protein-coupled (GPCR) family that recognize both exogenous and endogenous "danger" signals, and can trigger inflammation while FPR2/ALX activates resolution ([@bb2870]). Genetic deletion of FPR1 in gastric cancer cells promoted angiogenesis and enhanced the response to pro-inflammatory cytokines and impairing inflammation resolution ([@bb2040]). The resolvin receptors (GPR32 for RvD1 and GPR 18 for RvD2) are down regulated during cancer progression in oral cancer cells ([@bb2875]). While both RvD1 and RvD2 inhibited oral tumor cell proliferation in vitro, RvD2 suppressed tumor growth in an oral squamous cell carcinoma xenograft models via macrophage efferocytosis and reduced tumor-derived cytokines/chemokines (TNF-α, IL-6, CXCL10, and MCP-1), CD11b^þ^Ly6G myeloid cell infiltration, nociception, reduction of tumor necrosis, and decreased neutrophil infiltration ([@bb2875]). Tissue resolvin of the D series was identified as potential biomarker in endometrial cancer patients and correlated with improved patient survival ([@bb0695]). Resolvin D1 (RvD1) also increases miR-138-5p expression by over 60-fold compared to control directly targeted FOXC1 to reduce cancer cell growth and invasion in NSCLC in vitro ([@bb0125]). RvD1 decreased cell viability and cell invasion in A549, H1299 and LLC cells in a dose-dependent manner and affected Akt and Erk1/2 phosphorylation ([@bb0125]). Specifically, in lung cancer, FOXC1 plays a critical role in tumor microenvironment to promoted cancer progression ([@bb0335]; [@bb1530]). RvD1 regulates the expression of several miRNAs. These studies establish the mechanistic linkage between miR-138-5p and inflammation resolution ([@bb0125]). RvD1 also inhibits skin inflammation via reducing cytokine levels including IL-1β, IL-6, IL-33, TNF-α, and oxidative stress induced by ultraviolet irradiation ([@bb2145]).

Epithelial mesenchymal transition (EMT) is a biological process that plays a critical role in cancer progression ([@bb1420]). Resolvins (RvD1 and RvD2) inhibit TGF-β1-induced epithelial mesenchymal transition (EMT) in lung cancer cells via their receptors ALX/FPR2 and GPR32 receptors, resulting in inhibition of ZEB1 expression ([@bb1430]). TGF-β1, one of the featured mediators in the resolution of inflammation and key components comprising the tumor microenvironment, can induce EMT of lung cancer cells. AT-RvD1 suppresses the TGF-β1-induced EMT by mTOR pathway inhibition reducing the expression of PKM2, which affects cellular energy metabolism and oxidative stress ([@bb1570]). Blocking the process of EMT can be an essential strategy in the development of anti-cancer drugs. EMT involves down-regulation of epithelial proteins such as *E*-cadherin and keratins and the acquisition of mesenchymal marker proteins, including vimentin and EMT-related transcription factors such as Snail1 and zinc-finger E-box binding 1 (ZEB1) ([@bb1420]). Snail, Twist, and ZEB transcription factors are well-known transcription factors involved in the EMT process. A cancer stem cell (CSC) is a cancer cell that undergoes a self-renewal and differentiation. Activation of EMT in cancer cells is closely related to the entry of cancer cells into CSC state ([@bb0355]). Resolvins (e.g. RvD1) impaired paracrine of activity of carcinoma-associated fibroblasts (CAFs)-derived COMP by targeting FPR2/ROS/FOXM1 signaling to inhibit EMT and cancer stemness in HCC in a receptor-dependent manner ([@bb2435]). Thus, RvD1 may be a potential agent to inhibit many cancers dependent on cancer stem cells such as hepatocellular carcinoma ([@bb2435]). CAFs-derived COMP induced EMT and cancer stem cell-like properties to promote invasion and metastasis of HCC ([@bb2435]), which was in accordance with previous findings that IL-6 secreted by CAFs confers stem-like properties in HCC via the upregulation of stemness-correlated transcription factors including Sox2, Oct4 and Nanog ([@bb1490]).

Resolvins (e.g. RvE1) also inhibit the oncoprotein c-Myc expression which is overexpressed in a large variety of human cancers such as colon cancer ([@bb3025]). The suppression of TNF-⍺-induced upregulation of c-Myc in normal cells was mediated through attenuation of NF-κB signaling ([@bb3025]). RvD1 stimulated c-Myc degradation through direct interaction with the ALX/FPR2 receptor ([@bb3025]). RvD1 induces cytotoxic activity and elevated caspase-3 activity in natural killer (NK) cells in pancreatic ductal adenocarcinoma cells (PDAC) cells ([@bb0935]). RvD1 and RvD2 also exhibited anti-inflammatory activity by inhibiting LPS-interferon (IFN)-γ-induced M1 polarization as well as promoting interleukin-4 (IL-4)-mediated M2a polarization. These differential polarization processes were mediated, at least in part, by protein kinase A. Thus, regulation of macrophage polarization using RvDs may be a potential therapeutic approach in the management of prostate cancer ([@bb2280])**.** The communication between human monocyte-derived M2-like macrophages (MDM) and cancer cells in co-incubations can strikingly modulate the biosynthetic capacities to produce bioactive LM including lipoxin A~4~, resolvin D2 and D5 were elevated after coculture with human A549 epithelial lung carcinoma cells ([@bb2740]).

Current therapy for HCC and hepatoblastoma includes resection, transplantation, radiofrequency ablation, chemoembolization and sorafenib ([@bb2615]). Resolvin D1 and E1 prevent liver injury and progression from hepatitis to liver cancer in murine models ([@bb1390]). Resolvins protect from acute liver injury (e.g. carbon tetrachloride) ([@bb0405]). Resolvin D1 and E1 prevent concanavalin A (Con A)-induced liver injury and the changes of hepatitis to liver cancer in mice by inhibition of inflammatory cytokine secretion and NF-κB/AP-1 activity ([@bb1390]). RvD1 and RvE1 inhibit Con A-induced liver injury, the production of TNF-α, IFN-γ, IL-2, IL-1β and IL-6, NF-κB and AP-1 signaling, TLR4, IκBα, IKKβ, MyD88, JNK, ERK and p38, and necrosis in mice ([@bb1390]). Resolvins (e.g. 17(*R*)-Resolvin D1) can regulate Toll-like receptor 4-mediated inflammatory responses of human macrophages to LPS and *E. coli* ([@bb1915]). Resolvins (e.g. RvD1) also inhibits the proliferation of LPS-treated liver cancer cells and reduces the expression and release of TNF-α, IL-1β and IL-6 at the protein and mRNA levels in LPS-treated liver cancer cells ([@bb1595]). In addition, RvD1 decreases p-ERK, p-JNK and p-p38 levels in LPS-treated liver cancer cells ([@bb1595]).

Resolvins may have the potential to resolve damaging inflammation generated by tobacco smoke, one of the most widespread worldwide carcinogens. Chronic secondhand exposure to tobacco smoke stimulated the levels of pro-inflammatory cytokines IL-17A, IL-6, IL-1β, and TNF-α in the lungs and impairs bacterial clearance from the lungs ([@bb0230])**.** Pro-resolution mediators such as resolvins suppressed macrophage production of smoke-induced pro-inflammatory cytokines, enzymes, and lipid mediators ([@bb0545]). Resolvins also increased anti-inflammatory cytokines, promoted an M2 macrophage phenotype, and restored cigarette smoke-induced defects in phagocytosis ([@bb0545])**.** Resolvin D1 (RvD1) suppressed production of pro-inflammatory mediators by primary human cells in a dose-dependent manner. RvD1 administered with cigarette smoke exposure reduced neutrophilic lung inflammation and production of pro-inflammatory cytokines, while upregulating the anti-inflammatory cytokine IL-10 in mice ([@bb1100])**.**

Alarmins such as high-mobility group box 1 (HMGB1) can disrupt the resolution of inflammation by inhibiting macrophage efferocytosis induced by SPMs ([@bb1260]). HMGB1 plays an important role in maintaining inflammation and can be actively released from various immune cells such as macrophages, monocytes, NK cells, dendritic cells, and endothelial cells, as well as from dead (e.g necrotic) cells ([@bb2175]). HMGB1 enhances inflammatory reactions by potentiating the activity of pro-inflammatory mediators such as LPS and cytokines, and by suppressing the phagocytosis of apoptotic neutrophils ([@bb0150]; [@bb1540]). HMGB1 suppresses resolvin D1-induced phagocytosis via induction of resolvin D1-inactivating enzyme, 15-hydroxyprostaglandin dehydrogenase ([@bb1260]). HMGB1 suppressed RvD1-enhanced phagocytosis of MDA-MB-231 cancer cells and gene silencing of HMGB1 restored the phagocytic capability of MDA-MB-231 cells ([@bb1260]). Hepatocellular carcinoma ensues in the presence of excessive hepatic apoptosis and necroptosis in the tumor microenvironment which directs lineage commitment to either hepatocellular carcinoma or intrahepatic cholangiocarcinoma ([@bb2215]). The clearance of necroptotic cells are inefficiently taken up by macrophages in diseases characterized by impaired inflammation resolution ([@bb0840])**.** Necroptotic cells are inefficiently taken up by macrophages because they have increased surface expression of CD47, a "don\'t eat me" signal ([@bb0840]). Resolvin D1 enhanced the clearance of necroptotic cells in advanced murine plaques by the release of the "eat me signal" calreticulin from macrophages in a CDC42 dependent manner ([@bb0840])**.**

8.7. SPMs in humans {#s0125}
-------------------

Evidence in humans demonstrates the importance of pro-resolving lipid mediators in the cancer patients. The pro-inflammatory response in response to hepatobiliary surgery is associated with low circulating concentrations of lipoxin A~4~ and resolvins of the D series which were the opposite of IL-6 and cortisol which were elevated after surgery for liver tumors ([@bb0345]). The systemic inflammatory markers in the plasma C-reactive protein (CRP) and interleukin-6 were decreased in lung cancer patients administered EPA and DHA supplementation undergoing chemotherapy in a double-blind placebo-controlled study ([@bb0750]). In another study, compared with healthy volunteers, the levels of serum pro-inflammatory cytokines in colon cancer patients increase while the level of RvD1 decreased significantly associated with higher TNM stage of colon cancer ([@bb3040]). Concentrations of IL-6, IL-1β, IL-10 and TNF-α gradually increased with the advancement of TNM staging ([@bb3040]). In stage III, concentrations of IL-6, IL-1β, and IL-10 were the highest, TNF-α concentration was the highest in stage IV. RvD1 concentration gradually decreased with the advancement of TNM staging ([@bb3040]).

Resolvin E1 (RvE1) plays an key role in the resolution of acute inflammation when immunonutrition is supplemented with EPA in patients undergoing a severely stressful operation ([@bb2570]). Pre-operative immunonutrition reduced pro-inflammatory responses and protected against the aggravation of post-operative complications in patients undergoing major hepatobiliary resection ([@bb2570]). In clinical randomized trials focused on dietary interventions that can boost SPMs, omega-3 fatty acids increased resolvins (e.g. RvE1) in patients undergoing hepatobiliary surgery for liver cancer, resulting in lower rates of infections, complications, and disease progression ([@bb2570]). The omega-3 fatty acid Lovaza stimulates SPM production in coronary artery disease patients ([@bb0680]). SPMs were also boosted in military personnel and in traumatic brain injury patients administered with substrate supplementation ([@bb0255]). Peripheral blood markers of inflammation as well as inflammation resolution markers (e.g. resolvins) have been identified in cancer patients. ω-3 PUFAs exhibit anti-tumor activity in a variety of cancers such as breast cancer. SPMs may account for the anti-inflammatory and anti-cancer activity of ω-3 PUFA at least in part.

Maresins (e.g. MaR1) can also inhibit EMT of mouse type II alveolar epithelial cells and improve bleomycin-induced lung fibrosis ([@bb2715]). Protectin DX (PDX), a PD1 isomer that is a double lipoxygenation product, reverses bleomycin-induced lung fibrosis by reversing EMT and alleviates acute kidney injury ([@bb0660]; [@bb1480]). Docosahexaenoic acid (DHA) with A549 lung cancer cells can generate maresins (e.g. MaR1) and protectins (e.g. PD1/NPD1). The role of maresins and protectins in cancer remain of interest in the years ahead now that they are widely available.

8.8. Annexin A1 and Gaseous mediators {#s0130}
-------------------------------------

In addition to SPMs, inflammation resolution is also controlled by a variety of endogenous mediators including protein/peptide mediators, such as annexin A1 and annexin A1--derived peptides which stimulate inflammation resolution ([@bb1960]). Interestingly, estrogen can stimulate resolution of inflammation in macrophages ([@bb2610]). Other pro-resolution mediators are IL-10, gases (e.g. carbon monoxide and hydrogen sulfide), TGF-β, formyl-Peptide Receptors, Selenoproteins, Galectin-1, and nucleotides (e.g. adenosine and inosine)^,^([@bb0090]; [@bb1840]; [@bb2645]). Drugs that stimulate resolution include aspirin, statins, omega-3 fatty acids, annexin A1 and annexin A1-derived peptides, statins, glucocorticoids, diclofenac, α-melanocyte stimulating hormone, erythropoietin, kinase inhibitors, galectins, chemerin, adrenocorticotropic hormone, gaseous mediators (e.g. hydrogen sulfide and carbon monoxide), purine (adenosine) as well as neuromediators and pioglitazone ([@bb2260]). Drugs that may be resolution toxic include NSAIDs, COX-2 inhibitors, and lidocaine which impair efferocytosis ([@bb2260]).

8.9. Diet, exercise and supplementation {#s0135}
---------------------------------------

Both omega-3 fatty acids and aspirin, which are known to reduce cancer risk, trigger the body\'s production of resolvins ([@bb2445]). Although resolvins inhibit primary tumor growth at doses over *10,000 fold less* than omega-3 fatty acids, due to their rapid metabolism in vivo, an alternative approach for clinical application of SPMs in cancer is to increase their endogenous synthesis through dietary and pharmacologic intervention ([@bb2230]). Omega-3 polyunsaturated fatty acids are precursors for many SPMs; for example, DHA is the substrate that aspirin-acetylated COX-2 converts to aspirin-triggered resolvins (e.g. AT-RvD1). In human subjects, dietary intake of DHA and EPA with aspirin treatment effectively increased plasma resolvin levels ([@bb2230]). Similarly, mice fed a high omega-3 diet exhibited high levels of resolvins and omega-3 fatty acids in their tissues, serum, and plasma.

Thus, dietary interventions have been suggested as an approach to carcinogen associated inflammation. For example, in a DMBA-induced mammary carcinogenesis model low dose EPA and DHA demonstrated chemopreventive activity ([@bb1865]). A diet high in omega-3 s opposes the western diet, high in omega-6 fatty acids, which promotes inflammatory macrophage- and colitis-associated colon carcinogenesis ([@bb1320]). Importantly, DHA supplementation may increase the efficacy of HCCA patients receiving sorafenib via increased anti-angiogenic and anti-tumorigenic lipids such as 19,20-epoxydocosapentaenoic acid (EDP) ([@bb1450]; [@bb2935]). Additionally, diets, based off elite crop varieties containing anticancer effects have been demonstrated to reduce hepatocarcinogenesis from NDEA by downregulating TNF-α/IL-6, increasing antioxidants, and increasing apoptosis without stimulating regenerative proliferation ([@bb3015]). Additionally, EPA suppressed IL-6-induced chronic inflammation in high fat diet and carcinogen-induced HCC ([@bb1165]). In a colon cancer model EPA also reduced MMP9 cytokine production via NOTCH1 signaling to exhibit protective effects ([@bb0720]). Alternatively, caloric restriction has been suggested as a mechanism to alter metabolic pathways in NDEA-induced HCC rather than diet leading to altered inflammation, oxidative stress, cell migration, injury and oncogenesis ([@bb1985]). Human plasma and serum found to consist of eicosanoids and SPMs, additional omega-3 or acetylsalicylic acid supplementation also increased plasma SPM levels inducing increased phagocytosis ([@bb0495]). In a randomized double blinded placebo controlled study marine oil supplements containing fatty acid precursors increased SPM levels in blood samples and reprogramed blood cells to a pro-resolution phenotype ([@bb2375]). An additional clinical trial demonstrated efficacy of fish oil to benefit patients undergoing gastrointestinal surgery via regulation of TNF-α and NF-κB ([@bb2685]). Stretching of connective tissue stimulates murine production of SPMs including resolvins, suggesting the potential for beneficial cancer protective activity of exercise ([@bb0220]).

However, benefits of dietary intervention and fatty acid supplements results are not always validated. In one study dietary fish oil enhanced azaserine-induced pancreatic carcinogenesis in rats ([@bb0080]). Fish oil supplementation may require additional regulation of what lipids specifically are in the product as it is not one specific compound. In a model of carcinogen-induced inflammatory colon cancer the EPA:AA lipid ratio helped predict PGE~2~ levels in the tumor tissue of mice fed with a fish oil diet or western fat diet. Thus, the beneficial activity of diets on lipid production may depend on the pre-existing tumor lipid microenvironment ([@bb0630]). While fish oils have been suggested as an important source of antioxidants one group found environmental pollutants to outweigh the benefits of antioxidants in fish oil without proper regulation of persistent organic pollutants ([@bb1090]). In a study of women diagnosed with breast cancer omega-3 fatty acid intake did not affect overall breast cancer risk, although it did marginally reduce the risk of estrogen and progesterone receptor positive breast cancers, which was increased with omega-6 fatty acid intake ([@bb1330]).

8.10. Epoxyeicosanoids and sEH inhibition {#s0140}
-----------------------------------------

Epoxyeicosatrienoic acid (EETs) are lipid signaling molecules which act as autocrine and paracrine mediators of proliferation, migration, and inflammation in several tissues ([@bb2380]). EETs are fatty acid epoxides (EpFA) produced via the epoxidation of arachidonic acid catalyzed by cytochrome P450 (CYP) enzymes. Most CYP enzymes are general oxidases showing varying degrees of selectivity for the substrate and the product formed. In normal animals CYP2C8 or CYP2J2 appear largely responsible for production of EpFA and are metabolized by soluble epoxide hydrolase (sEH) to the corresponding 1, 2-diols. Members of the CYP4A, CYP2C, and CYP2J families of epoxygenases are among the most extensively studied([@bb0770]), however, in animals with induced cytochrome P450s other families may dominant production of EpFA. While CYP4A enzymes produce the vasoconstrictor 20-hydroxyeicosatrienoic acid (20-HETE), the CYP2C and CYP2J enzymes convert arachidonic acid to the bioactive epoxyeicosatrienoic acids (EETs), including 5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET. EETs are metabolized by soluble epoxide hydrolase (sEH) to less active dihydroxyeicosanoic acids (DHETs). EETs, which function primarily as autocrine and paracrine mediators of arachidonic acid-induced relaxation in the cardiovascular and renal systems, are short-lived and quickly metabolized in most tissues ([@bb0320]; [@bb0775]). EETs secreted mainly by endothelial cells have critical roles in cellular proliferation, migration and inflammation; their major target cells are blood vessels ([@bb2380]). The EET producing enzymes of the CYP2C and CYP2J subfamilies have been found in endothelial cells (ECs) in vitro and in vivo ([@bb0770]; [@bb2025]). Indeed, CYP2C enzymes are induced by hypoxia, and endothelial cells are a major source of EETs during inflammation and angiogenesis. Targeted inhibition of the EET-inactivating enzyme sEH raises the levels of the cardioprotective EETs. Thus, soluble epoxide hydrolase (sEH) inhibitors are in clinical development being evaluated in phase II clinical trials for hypertension. The role of EETs and soluble epoxide hydrolase inhibitors as classical mediators of inflammation offer targets for drugs directed towards the tumor stroma for cancer therapy.

sEH inhibition and epoxy fatty acids are dual functioning to inhibit inflammation-induced carcinogenesis and enhance NSAID-induced ulcer healing at the site of inflammation via suppressing reactive oxygen species, improved mitochondrial function ([@bb1240]). sEH is overexpressed in ulcerative colitis (UC)-associated dysplasia and adenocarcinoma ([@bb2975]). EETs are anti-inflammatory and inhibit cytokine-mediated endothelial cell adhesion preventing leukocyte infiltration via NF-κB ([@bb1860]). sEH inhibition inhibits inflammatory bowel disease (IBD) and IBD-tumor development including dextran sulfate sodium (DSS)-induced carcinogenesis via suppressed cytokines/chemokines including MCP-1, iNOS, VCAM-1, IL-1β and TNF-α ([@bb2980]; [@bb2985]; [@bb2975]).

Inhibition of sEH inhibits chronic pancreatitis and the progression of pancreatic intraepithelial neoplasms (PanIN) via dual inhibition of sEH and RAF1 proto-oncogene serine/threonine kinase (c-RAF)([@bb1500]). Omega-3 epoxy fatty acids combined with a sEH inhibitor inhibited pancreatic carcinoma via anti-inflammatory, anti-proliferation, reduced mutant Kras-activated signals, and anti-angiogenic activity ([@bb2780]). Soluble epoxide hydrolase (sEH) inhibitors stabilize arachidonic acid-derived epoxyeicosatrienoic acids (EETs), which also stimulate inflammation resolution by promoting the production of pro-resolution mediators (e.g. lipoxins), activating anti-inflammatory processes, and preventing the cytokine storm. sEH inhibition can inhibit vascular permeability to prevent diabetic retinopathy ([@bb1105]).

Poly-unsaturated fatty acids also generate EETs which are metabolites of the omega-6 fatty acid arachidonic acid ([@bb1590]; [@bb2935]). EETs may potently downregulate endoplasmic reticulum (ER) stress responses as demonstrated in response to cigarette smoke damage ([@bb2895]). Thus, inhibition of sEH may allow for their stability and prolonged effects and has demonstrated pro-resolution activity such as stimulation of SPMs and activating anti-cytokine programs in multiple inflammatory diseases, including those which are risk factors for cancer induction ([@bb2190]; [@bb2675]; [@bb2860]; [@bb2895]). Importantly, the sEH eicosanoid pathway has been suggested to be involved in the progression of colorectal cancer, including obesity-associated cancer ([@bb2945]). Inflammatory mediators, including angiotensin, TNF-α and NF-κB can upregulate sEH expression in immune cells ([@bb0195]). sEH inhibitors (sEHI) downregulate NF-κB and other inflammatory markers leading to decreased pro-inflammatory cytokines and nitric oxide metabolites and upregulates lipoxins to generate resolution ([@bb2190]). In addition to downregulating a series of pro-inflammatory cytokines, EETs promote macrophage phagocytosis ([@bb0310]), which may have implications for the clearance of carcinogen-generated dead cells. Importantly, inhibition of sEH also promotes the generation of SPMs such as lipoxin generation ([@bb1900]). A metabolomics approach identified a critical role for cytochrome P450 (CYP)-generated epoxygenerated fatty acids and sEH-mediated eicosanoids were elevated in the plasma and colon of azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced colon cancer ([@bb2695]).

However, the role of EETs in cancer is complex as these epoxyeicosanoids may stimulate pro-angiogenic and pro-tumorigenic mechanisms ([@bb1160]; [@bb1925]). The CYP3A4 produced EETs play a role in breast cancer progression, including in tamoxifen-resistant subsets via proliferation, angiogenesis, and migration ([@bb2495]). While EETs can be mildly pro-angiogenic, inhibition of sEH prevents angiogenic diseases such as diabetic retinopathy ([@bb1105]). Interestingly, EET-induced angiogenesis is suppressed by simultaneous inhibition of COX-2 by preventing COX mediated metabolism to pro-angiogenic lipids ([@bb2065]). Importantly, sEHIs may also reduce the toxicities of NSAIDs and COX-2 inhibitors via anti-inflammation and inhibition of oxidative injury as well as barrier breakdown ([@bb1240]). To minimize the pro-angiogenic activity of sEH inhibitor and the GI toxicity of COX-2 inhibitors, a novel COX-2/sEH inhibitor (PTUPB) was synthesized which potently inhibits inflammation ([@bb1140]). Cancer progression is stimulated by inflammation, fibrosis, and oxidative stress. Dual COX-2/sEH inhibition via PTUPB inhibits allergic airway inflammation, pulmonary fibrosis, kidney injury and sepsis via anti-oxidative stress ([@bb0620]; [@bb1155]; [@bb3000]; [@bb2960]). Dual COX-2/sEH inhibition inhibits primary tumor growth including glioblastoma growth, metastasis and potentiates the antitumor efficacy of chemotherapeutic agents such as cisplatin ([@bb1480]; [@bb2700]; [@bb2930]). A novel dual COX-2/sEH inhibitor (PTUPB) inhibits debris-stimulated ovarian tumor growth by preventing an eicosanoid and cytokine surge of pro-inflammatory and pro-angiogenic mediators ([@bb0825]). PTUPB inhibits high-fat diet-induced non-alcoholic fatty liver disease via inhibition of fibrosis, collagen deposition and pro-inflammatory cytokines ([@bb2430]). sEH is a therapeutic target as it is upregulated in obesity-induced colonic inflammation and sEH inhibition reduces obesity-induced activation of Wnt signaling in mice ([@bb2675]). Notably, carcinogen-induced cell death dose-dependently promotes tumor dormancy escape and progression by triggering oxidative stress as well as an eicosanoid/cytokine storm of pro-inflammatory mediators ([@bb0760]). In contrast, dual COX-2/sEH inhibition prevents inflammation-initiated tumor growth by preventing the eicosanoid/cytokine storm and reducing oxidative stress, as well as by promoting macrophage-mediated efferocytosis of tumor debris ([@bb0760]). Thus, inhibition of sEH may synergize with COX-2 inhibition while reducing the toxicity of COX-2 inhibition.

Thus, EETs may additionally be a novel approach to resolving carcinogen-induced inflammation via anti-inflammatory signaling and stimulation of macrophage phagocytosis. Importantly, in bronchiolar cells in which oxidative stress reduced lipoxin production, sEHIs stimulated pro-resolution mechanisms by stimulating the levels of lipoxins ([@bb1900]). Stimulation of resolution of inflammation, via SPMs or EETs, may be a novel chemopreventive approach to carcinogen-induced cycles of inflammation, cell death, oxidative stress, and carcinogenesis ([Fig. 4](#f0020){ref-type="fig"}).

9. Outlook {#s0145}
==========

Cancer accounts for over 8 million deaths annually worldwide and presents one of the largest disease morbidity and mortality ([@bb0525]). The prognosis for patients with cancer remains poor. Despite many exciting advances in research, many cancers remain deadly unless diagnosed early before advanced metastatic disease**.** The most effective treatment for patients is prevention and early detection. While carcinogens induce inflammation, a hallmark of cancer and a key characteristic of their pro-tumorigenic activity ([@bb0960]; [@bb1655]; [@bb2350]), they also disrupt the resolution of inflammation. Thus, the loss of inflammation resolution is an emerging mechanism of cancer pathogenesis ([@bb0850]; [@bb1545]; [@bb1930]; [@bb2260]; [@bb2420]; [@bb2425]; [@bb2875]). Carcinogens continue to play a large role in the disease and social burdens of cancer globally. However, genotoxic mechanisms alone may not be sufficient for carcinogenesis and increased tumor risk ([@bb0270]; [@bb1225]), and more studies are required to further characterize nongenotoxic mechanisms including "failed" inflammation resolution. There is a malignant pro-tumorigenic feedback loop between apoptosis, inflammation, DNA damage, and carcinogenesis. Chronic inflammation and oxidative stress are largely intertwined processes which contribute via feedback loops to a microenvironment of stress, injury, and regeneration ([@bb1890]). Initial carcinogen exposure induces inflammatory pathways and signaling through NF-κB leads to cytokine production, inflammatory infiltrates, and reactive oxygen species in a pro-tumorigenic environment. Controlling the local and systemic inflammatory response will be essential to prevent carcinogen-induced cancers. Stimulation of resolution via supplementation of specifically pro-resolution lipid mediators may be a potent and less toxic non-immunosuppressive approach to reduce and prevent carcinogenesis at an early stage ([@bb0850]). Importantly, SPMs, including resolvins, lipoxins, and protectins, as well as sEH inhibitors are currently in clinical trials for other inflammatory diseases and could be rapidly translated for the management of carcinogen-induced cancers. Pro-resolution therapies can complement current anti-carcinogen strategies via debris clearance and inflammatory cytokine suppression. Further studies including human cancer trials are needed to evaluate the stimulation of resolution of inflammation to prevent and treat carcinogen-induced cancers.
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